Details of Disease

Disease Name

B-cell lymphoma

Disease Class

2A86: B-cell lymphoma

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DISIH1YQ: B-cell lymphoma

ICD-11

ICD-11: 2A86

ICD-10

ICD-10: C85.1

ICD-9

ICD-9: 202.8

Expand ICD-11

'2A86; '2A86.1; '2A86.0; '2A86.2; '2A85

Expand ICD-10

'C85.1

Expand ICD-9

202.8

Disease Identifiers

MONDO ID

MONDO_0018905

MESH ID

D016403

UMLS CUI

C0079744

MedGen ID

86954

HPO ID

HP:0012191

Orphanet ID

544

SNOMED CT ID

109969005

General Information of Disease (ID: DISIH1YQ)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Zanubrutinib	DMJWRQP	Approved	NA	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 71 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CPI-613	DM5XUQL	Phase 3	Small molecular drug	[1]
INCB24360	DMIJGT9	Phase 3	Small molecular drug	[1]
CD19 CAR T cells	DM32148	Phase 2/3	CAR T Cell Therapy	[2]
CART-19	DMHQKN6	Phase 2	CAR T Cell Therapy	[3]
CD19-targeting CAR T cells	DMQJBUK	Phase 2	CAR T Cell Therapy	[4]
Cerdulatinib	DMSCR2H	Phase 2	NA	[1]
DI-Leu16-IL2	DMTLB92	Phase 2	Recombinant protein	[5]
GS-4059	DMHQV6R	Phase 2	NA	[1]
GS-9973	DMKWCTR	Phase 2	Small molecular drug	[6]
JCAR015	DM89ASO	Phase 2	CAR T Cell Therapy	[7]
MT-3724	DMCNL7Z	Phase 2	Recombinant?protein	[8]
Reviroc	DMHUCQQ	Phase 2	Small molecular drug	[9]
XLCART001	DMVB8EO	Phase 2	CAR T Cell Therapy	[10]
4SCAR19 and 4SCAR123	DMYPQT4	Phase 1/2	CAR T Cell Therapy	[11]
4SCAR19 and 4SCAR20	DMFVTSG	Phase 1/2	CAR T Cell Therapy	[11]
4SCAR19 and 4SCAR22	DM8CMUW	Phase 1/2	CAR T Cell Therapy	[11]
4SCAR19 and 4SCAR30	DMUYFS1	Phase 1/2	CAR T Cell Therapy	[11]
4SCAR19 and 4SCAR38	DMZKFU7	Phase 1/2	CAR T Cell Therapy	[11]
4SCAR19 and 4SCAR70	DMKC8F9	Phase 1/2	CAR T Cell Therapy	[11]
4SCAR19 cells	DMIY1ZB	Phase 1/2	CAR T Cell Therapy	[12]
4SCAR19/22 T cells	DMI8TW3	Phase 1/2	CAR T Cell Therapy	[13]
Anti-CD19 and Anti-CD20 CAR-T Cells	DMLFB25	Phase 1/2	CAR T Cell Therapy	[14]
Anti-CD19 CAR T cells	DMS326R	Phase 1/2	CAR T Cell Therapy	[15]
Anti-CD19 CAR-T cells	DM92CUG	Phase 1/2	CAR T Cell Therapy	[16]
BI 1206	DMTOMWB	Phase 1/2	Antibody	[17]
CART20	DMKGU5F	Phase 1/2	CAR T Cell Therapy	[18]
CD137 CAR-T Cell	DMHMC19	Phase 1/2	CAR T Cell Therapy	[19]
CD19 and CD20 CAR-T Cells	DMRJ3ND	Phase 1/2	CAR T Cell Therapy	[20]
CD19 and CD22 CAR-T Cells	DM581CS	Phase 1/2	CAR T Cell Therapy	[20]
CD19 CART	DM69A1W	Phase 1/2	CAR T Cell Therapy	[21]
CD19 targeted chimeric antigen receptor T cells	DM8RXFB	Phase 1/2	CAR T Cell Therapy	[22]
CD22 CAR-T	DM40NEB	Phase 1/2	CAR T Cell Therapy	[23]
CPI-1205	DM3XWJ8	Phase 1/2	NA	[1]
CYT-0851	DME6NMJ	Phase 1/2	Small molecular drug	[24]
JCAR014	DMTMVEW	Phase 1/2	CAR T Cell Therapy	[25]
UCART019	DMRJK26	Phase 1/2	CAR T Cell Therapy	[26]
Vecabrutinib	DM8A5E0	Phase 1/2	NA	[1]
Anti-CD19 CAR-T cell therapy	DMB7JS4	Phase 1	NA	[8]
Anti-CD19-CAR	DMWKYSM	Phase 1	CAR T Cell Therapy	[27]
Anti-CD19-CAR T cells	DMYQFCN	Phase 1	CAR T Cell Therapy	[28]
BGB-10188	DM84LXE	Phase 1	Small molecular drug	[29]
BGB-16673	DM7X6IB	Phase 1	PROTAC	[30]
BGB-3113	DMIF9DZ	Phase 1	NA	[1]
CART-19	DM1R8P4	Phase 1	CAR T Cell Therapy	[31]
CarVAC	DM39LPN	Phase 1	CAR T Cell Therapy	[32]
CD19 CAR T	DM4PWNU	Phase 1	CAR T Cell Therapy	[33]
CD19/CD22 CAR T-Cells	DMKA2FL	Phase 1	CAR T Cell Therapy	[34]
CD19/CD22 Chimeric Antigen Receptor T Cells	DMPADR1	Phase 1	CAR T Cell Therapy	[35]
CD20-CAR-T Cells	DM37OJN	Phase 1	CAR T Cell Therapy	[36]
CD20-CD19 cCAR	DMUYTW3	Phase 1	CAR T Cell Therapy	[37]
Chi Lob 7/4	DMSOB5D	Phase 1	NA	[38]
CTX-101	DMHK9WR	Phase 1	CAR T Cell Therapy	[39]
DTRMWXHS-12	DM5AGKV	Phase 1	Small molecular drug	[1]
Duvortuxizumab	DM3P0H1	Phase 1	NA	[8]
ET019002	DMRW1Q3	Phase 1	CAR-T cell therapy	[40]
ET019003	DMUOM5P	Phase 1	CAR-T cell therapy	[41]
FT500	DMA18BH	Phase 1	Cell therapy	[42]
IC9-CAR19 T cells	DMNCBIU	Phase 1	CAR T Cell Therapy	[43]
ICAR19 CAR-T cells	DMHG4Q9	Phase 1	CAR T Cell Therapy	[44]
KA2237	DMFKEVO	Phase 1	NA	[1]
KITE-363	DMIZPF4	Phase 1	CAR-T cell therapy	[45]
KUR-502	DMS9LVC	Phase 1	CAR T Cell Therapy	[46]
ONO-4059	DMC29LV	Phase 1	NA	[47]
PZ01 CAR-T cells	DMRGWDB	Phase 1	CAR T Cell Therapy	[48]
STRO-001	DMOPQRE	Phase 1	NA	[1]
TG-1801	DM3K4FY	Phase 1	Antibody	[49]
TNB-486	DMSRICG	Phase 1	Antibody	[50]
TRPH-222	DMSLQW2	Phase 1	Antibody drug conjugate	[51]
XmAb13676	DMXTOCE	Phase 1	NA	[1]
CAR-CD19 T cell	DMXU2D1	Clinical trial	CAR T Cell Therapy	[52]
CD19CART	DMF936G	Clinical trial	CAR T Cell Therapy	[53]
------------------------------------------------------------------------------------


⏷ Show the Full List of 71 Drug(s)

This Disease is Treated as An Indication in 4 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Naked DNA (B-cell lymphoma)	DMZL0J8	Discontinued in Phase 2	NA	[54]
TG-1042	DMS4BUK	Discontinued in Phase 2	NA	[55]
ASIbcl vaccine	DMMQNI1	Terminated	NA	[57]
Non-Hodgkin lymphoma vaccine	DMVOW16	Terminated	NA	[58]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ATA2431	DM34FEA	Preclinical	CAR T Cell Therapy	[56]
ATA3219	DMJTYH3	Preclinical	CAR T Cell Therapy	[56]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GBR-401	DM7E765	Investigative	NA	[59]
HuMax-CD32b	DMY8FT4	Investigative	NA	[59]
Lymphozene	DM5T9OV	Investigative	NA	[59]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 203 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ALK	TTPMQSO	Limited	Genetic Variation	[60]
CASR	TTBUYHA	Limited	Biomarker	[61]
CAT	TTPS279	Limited	Biomarker	[62]
CCND3	TT1JXNR	Limited	Genetic Variation	[63]
CDK1	TTH6V3D	Limited	Biomarker	[64]
CHM	TTOA18V	Limited	Biomarker	[65]
CRBN	TTDKGTC	Limited	Biomarker	[66]
FBXO11	TT6G10V	Limited	Biomarker	[67]
IRF8	TTHUBNK	Limited	Biomarker	[68]
LAMP1	TTC214J	Limited	Altered Expression	[69]
NFKB2	TTKLNRV	Limited	Biomarker	[70]
NR1I3	TTRANFM	Limited	Biomarker	[61]
P2RY12	TTZ1DT0	Limited	Biomarker	[71]
PDPK1	TTYMGWX	Limited	Altered Expression	[72]
PRDX4	TTPBL9I	Limited	Biomarker	[62]
ROR1	TTDEJAU	Limited	Biomarker	[73]
SGK1	TTTV8EJ	Limited	Biomarker	[74]
SLC16A3	TTG6VD5	Limited	Biomarker	[75]
SOD2	TT9O4C5	Limited	Biomarker	[62]
TNFSF13B	TTWMIDN	Limited	Altered Expression	[76]
TXNIP	TTTLDZK	Limited	Biomarker	[62]
ACVRL1	TTGYPTC	Disputed	Altered Expression	[77]
CDKN1C	TTBSUAR	Disputed	Genetic Variation	[78]
IL21R	TTZO9B0	Disputed	Altered Expression	[79]
PTPRC	TTUS45N	Disputed	Altered Expression	[80]
ABCG2	TTIMJ02	moderate	Biomarker	[81]
AICDA	TTKRTP6	moderate	Biomarker	[82]
BTK	TTGM6VW	moderate	Biomarker	[83]
CCR8	TTE836A	moderate	Biomarker	[84]
EZH2	TT9MZCQ	moderate	Altered Expression	[85]
HDAC6	TT5ZKDI	moderate	Biomarker	[86]
IRF1	TT4TU3L	moderate	Biomarker	[87]
ITPR3	TTH1769	moderate	Biomarker	[88]
LMO2	TTFX379	moderate	Altered Expression	[89]
MCL1	TTL53M6	moderate	Altered Expression	[90]
MTA1	TTO4HUS	moderate	Altered Expression	[91]
PAX5	TTA4REJ	moderate	Genetic Variation	[92]
PIM2	TT69J2Z	moderate	Biomarker	[93]
PTPRJ	TTWMKXP	moderate	Biomarker	[94]
SDC1	TTYDSVG	moderate	Biomarker	[95]
SLC16A1	TTN1J82	moderate	Biomarker	[75]
SYK	TT2HUPM	moderate	Biomarker	[96]
ABCB1	TT3OT40	Strong	Biomarker	[97]
ABL2	TT1A6HL	Strong	Biomarker	[71]
AMACR	TTLN1AP	Strong	Genetic Variation	[98]
ANTXR2	TTOD34I	Strong	Biomarker	[99]
BCL11A	TTR61MW	Strong	Biomarker	[100]
BCL2A1	TTGT9C7	Strong	Altered Expression	[90]
BCL2L2	TTQ79W8	Strong	Altered Expression	[101]
BLK	TTNDSC3	Strong	Altered Expression	[102]
BMP6	TT07RIB	Strong	Posttranslational Modification	[103]
BTG1	TTL7N2W	Strong	Genetic Variation	[104]
BTLA	TTER58P	Strong	Biomarker	[105]
CACNA1C	TTZIFHC	Strong	Altered Expression	[106]
CCNE1	TTCEJ4F	Strong	Altered Expression	[107]
CCR1	TTC24WT	Strong	Biomarker	[108]
CD163	TTTZ9DE	Strong	Altered Expression	[109]
CD22	TTM6QSK	Strong	Biomarker	[110]
CD300A	TTI2YFK	Strong	Biomarker	[111]
CD38	TTPURFN	Strong	Biomarker	[112]
CD40	TT1ERKL	Strong	Altered Expression	[113]
CD5	TTEGYK1	Strong	Biomarker	[114]
CD70	TTNCIE0	Strong	Biomarker	[115]
CD79B	TTBN5I7	Strong	Genetic Variation	[116]
CD83	TTT9MRQ	Strong	Altered Expression	[117]
CD86	TT53XHB	Strong	Genetic Variation	[118]
CDC20	TTBKFDV	Strong	Altered Expression	[119]
CDC25C	TTESBNC	Strong	Altered Expression	[120]
CDC7	TTSMTDI	Strong	Biomarker	[121]
CDK2	TT7HF4W	Strong	Biomarker	[122]
CDK3	TTMYWL7	Strong	Biomarker	[123]
CDK9	TT1LVF2	Strong	Biomarker	[124]
CGB3	TTUH273	Strong	Altered Expression	[125]
CNP	TT71P0H	Strong	Genetic Variation	[126]
COPS5	TTSTNJR	Strong	Biomarker	[127]
CR2	TT0HUN7	Strong	Biomarker	[128]
CREBBP	TTFRCTK	Strong	Genetic Variation	[129]
CRY1	TT5MLZR	Strong	Genetic Variation	[130]
CXCR4	TTBID49	Strong	Biomarker	[131]
DCK	TTJOCE4	Strong	Biomarker	[132]
DIABLO	TTN74LE	Strong	Biomarker	[133]
EBI3	TTJF68X	Strong	Altered Expression	[134]
EED	TTFNJ4R	Strong	Biomarker	[135]
EML4	TT92GY4	Strong	Genetic Variation	[136]
EP300	TTGH73N	Strong	Biomarker	[129]
EPHA4	TTG84D3	Strong	Biomarker	[137]
EZR	TTE47YC	Strong	Altered Expression	[138]
FAS	TT7LTUJ	Strong	Altered Expression	[139]
FKBP4	TTHY0FT	Strong	Biomarker	[70]
GLMN	TT2UV5C	Strong	Altered Expression	[140]
GSTA1	TT4P8DE	Strong	Genetic Variation	[141]
HDAC9	TT8M4E1	Strong	Altered Expression	[142]
HK2	TTK02H8	Strong	Altered Expression	[143]
HLA-B	TTGS10J	Strong	Genetic Variation	[144]
HNMT	TT2B6EV	Strong	Biomarker	[145]
IL10RB	TTJTRMK	Strong	Altered Expression	[146]
IL21	TT9QEJ6	Strong	Genetic Variation	[147]
IL31RA	TT9HPX0	Strong	Biomarker	[148]
IL4R	TTDWHC3	Strong	Genetic Variation	[149]
INPP5D	TTTP2Z1	Strong	Altered Expression	[150]
IRAK4	TTILUKB	Strong	Biomarker	[151]
ITPR2	TTK9OV3	Strong	Altered Expression	[88]
KDM6B	TTDIJUQ	Strong	Biomarker	[152]
LAG3	TTNVXAW	Strong	Biomarker	[153]
LAIR1	TTSI7A8	Strong	Biomarker	[154]
LCK	TT860QF	Strong	Biomarker	[155]
LGMN	TTPTWV5	Strong	Biomarker	[156]
LTA	TTP73TM	Strong	Genetic Variation	[157]
LY6K	TT5GKHN	Strong	Biomarker	[158]
LYN	TT1RWNJ	Strong	Biomarker	[159]
MALT1	TTCI81G	Strong	Biomarker	[160]
MAP3K14	TT4LIAC	Strong	Biomarker	[161]
MAP3K20	TTTUZ3O	Strong	Genetic Variation	[162]
MAP3K7	TTJQT60	Strong	Altered Expression	[163]
MAP4	TT0VFPN	Strong	Genetic Variation	[164]
MAP4K4	TT6NI13	Strong	Biomarker	[161]
MAPK11	TT73U6C	Strong	Altered Expression	[165]
MASP2	TTR01E9	Strong	Genetic Variation	[166]
MBTPS1	TTNSM2I	Strong	Altered Expression	[113]
MELK	TTBZOTY	Strong	Altered Expression	[167]
METAP2	TTZL0OI	Strong	Altered Expression	[168]
MKNK1	TTEZAUX	Strong	Biomarker	[169]
MKNK2	TTRECN3	Strong	Biomarker	[169]
MSI2	TTTXQF6	Strong	Biomarker	[170]
MTAP	TTDBX7N	Strong	Altered Expression	[171]
NAPRT	TTVR1FW	Strong	Altered Expression	[172]
NEDD8	TTNDC4K	Strong	Altered Expression	[173]
NME1	TTDY8JH	Strong	Altered Expression	[174]
NODAL	TTK2O1Q	Strong	Biomarker	[175]
NOTCH2	TT82FVD	Strong	Altered Expression	[176]
NSD1	TTTSJ3H	Strong	Biomarker	[177]
PASK	TTC0V1J	Strong	Biomarker	[178]
PDCD1	TTNBFWK	Strong	Biomarker	[179]
PDCD1LG2	TTW14O3	Strong	Genetic Variation	[180]
PDE4A	TTZ97H5	Strong	Biomarker	[181]
PDE4B	TTVIAT9	Strong	Biomarker	[182]
PIK3CB	TT9H4P3	Strong	Biomarker	[73]
PIK3CD	TTGBPJE	Strong	Biomarker	[73]
PIK3CG	TTHBTOP	Strong	Biomarker	[73]
PIM1	TTTN5QW	Strong	Biomarker	[183]
PLK1	TTH4IP0	Strong	Biomarker	[184]
PLOD2	TT8MEUD	Strong	Altered Expression	[185]
PMEL	TT8MK59	Strong	Biomarker	[186]
PPARGC1B	TTKSQ3W	Strong	Biomarker	[187]
PRMT5	TTR1D7X	Strong	Altered Expression	[188]
PSIP1	TTH9LDP	Strong	Biomarker	[70]
PSMB5	TT68GPI	Strong	Altered Expression	[189]
PSMB9	TTOUSTQ	Strong	Biomarker	[190]
PTPN13	TT405FP	Strong	Posttranslational Modification	[191]
PTPN2	TTY8PUS	Strong	Altered Expression	[192]
PTPN6	TT369M5	Strong	Posttranslational Modification	[193]
RBCK1	TTIKUVC	Strong	Altered Expression	[194]
REL	TT1ZCTH	Strong	Altered Expression	[195]
RIPK4	TTB4S01	Strong	Biomarker	[196]
RNASEL	TT7V0K4	Strong	Biomarker	[197]
RNF34	TTEWDK1	Strong	Altered Expression	[198]
RPS6KA1	TTIXKA4	Strong	Biomarker	[178]
RPS6KA2	TT0ZW9O	Strong	Biomarker	[178]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[178]
RPS6KB1	TTG0U4H	Strong	Biomarker	[178]
S1PR2	TTVSMOH	Strong	Biomarker	[113]
SCT	TTOBVIN	Strong	Biomarker	[199]
SELPLG	TTS5K8U	Strong	Altered Expression	[185]
SIK2	TTCUGZR	Strong	Biomarker	[200]
SKP2	TT5B2EO	Strong	Biomarker	[201]
SLAMF7	TT7ILZ1	Strong	Biomarker	[202]
SLC19A1	TT09I7D	Strong	Posttranslational Modification	[203]
SLC5A7	TTRV7W3	Strong	Biomarker	[204]
SLC8A1	TTCF82X	Strong	Altered Expression	[70]
SMAD1	TT9GR53	Strong	Altered Expression	[205]
SOCS1	TT8COJM	Strong	Genetic Variation	[206]
STAT6	TTWOE1T	Strong	Posttranslational Modification	[192]
TNFAIP3	TT5W0IO	Strong	Genetic Variation	[207]
TNFRSF13C	TT7NJSE	Strong	Altered Expression	[161]
TNFRSF14	TTWGTC1	Strong	Altered Expression	[185]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[208]
TRB	TT84HCW	Strong	Biomarker	[209]
TRPM4	TTJ2HKA	Strong	Altered Expression	[210]
UCHL1	TTX9IFP	Strong	Biomarker	[211]
UCHL5	TTSX29Z	Strong	Biomarker	[189]
UGCG	TTPHEX3	Strong	Biomarker	[212]
USP14	TTVSYP9	Strong	Biomarker	[189]
VTCN1	TTCK85E	Strong	Altered Expression	[213]
WEE1	TTJFOAL	Strong	Biomarker	[214]
WRN	TT2H5WQ	Strong	Genetic Variation	[215]
XPO1	TTCJUR4	Strong	Genetic Variation	[216]
ZAP70	TTUMHT8	Strong	Biomarker	[217]
B2M	TTY7FKA	Definitive	Biomarker	[218]
CD37	TTFCW29	Definitive	Biomarker	[219]
CD58	TT5KSBY	Definitive	Biomarker	[220]
CMA1	TT8VUE0	Definitive	Biomarker	[75]
FCGR2A	TTXT21W	Definitive	Biomarker	[221]
FOXO1	TTLRVIA	Definitive	Altered Expression	[222]
GLI1	TTJOMH6	Definitive	Altered Expression	[223]
JAK1	TT6DM01	Definitive	Altered Expression	[224]
LGALS1	TTO3NYT	Definitive	Biomarker	[225]
MKI67	TTB4UNG	Definitive	Biomarker	[226]
NCAM1	TTVXPHT	Definitive	Biomarker	[227]
NEK2	TT3VZ24	Definitive	Altered Expression	[228]
PTPN1	TTELIN2	Definitive	Altered Expression	[229]
SLC22A2	TT0XOJN	Definitive	Altered Expression	[230]
SPN	TTOZAX0	Definitive	Altered Expression	[231]
TXN	TTZJ5U9	Definitive	Altered Expression	[232]
------------------------------------------------------------------------------------


⏷ Show the Full List of 203 DTT(s)

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ATP7A	DT0LT17	Strong	Biomarker	[233]
SLC27A1	DTKDTML	Strong	Altered Expression	[234]
------------------------------------------------------------------------------------

This Disease Is Related to 7 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
P4HA2	DE5EGK0	Strong	Biomarker	[235]
PGPEP1	DEVDR46	Strong	Biomarker	[236]
THOP1	DE95LJC	Strong	Biomarker	[237]
WARS1	DEPVE0M	Strong	Biomarker	[238]
WARS2	DEPTKBQ	Strong	Biomarker	[238]
CES2	DETHCPD	Definitive	Biomarker	[239]
MMEL1	DEYCUQ2	Definitive	Genetic Variation	[240]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DME(s)

This Disease Is Related to 264 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ARR3	OTRZ00CH	Limited	Biomarker	[61]
BACH2	OT17GS18	Limited	Biomarker	[70]
BCAS2	OTRMF2WY	Limited	Biomarker	[241]
BCL3	OT1M5B95	Limited	Biomarker	[76]
CDS1	OT2F591M	Limited	Biomarker	[242]
CLTC	OTBFASMA	Limited	Biomarker	[243]
CXADR	OT9ZP02A	Limited	Biomarker	[61]
DOHH	OTDRAT3F	Limited	Biomarker	[244]
EAF2	OTSOET5L	Limited	Biomarker	[245]
GOT2	OT6XBWN0	Limited	Altered Expression	[246]
IKZF1	OTCW1FKL	Limited	Genetic Variation	[247]
IMMP2L	OT9WGAFD	Limited	Biomarker	[241]
ITGAX	OTOGIMHE	Limited	Altered Expression	[248]
KLHL6	OTLDECOX	Limited	Biomarker	[249]
NECTIN2	OTIE0W6O	Limited	Biomarker	[241]
NOM1	OTWZSJJC	Limited	Biomarker	[243]
PASD1	OTZZWR7L	Limited	Altered Expression	[250]
PDLIM7	OTAZVODU	Limited	Biomarker	[113]
PRDM11	OT6DX554	Limited	Biomarker	[251]
PRDX3	OTLB2WEU	Limited	Biomarker	[62]
RAD1	OT886MA8	Limited	Biomarker	[244]
SEC31A	OT2U42AC	Limited	Biomarker	[243]
SLC16A4	OT1YXBKC	Limited	Biomarker	[75]
SOD3	OTIOZQAB	Limited	Biomarker	[62]
SPG7	OT8OY9ST	Limited	Biomarker	[61]
TP53BP2	OTOWJ2Y4	Limited	Altered Expression	[252]
TRIM13	OTQIUACB	Limited	Biomarker	[61]
CIB1	OT4BVCRU	Disputed	Biomarker	[253]
DOCK8	OTNQLL21	Disputed	Genetic Variation	[254]
MTA3	OTIA6C79	Disputed	Biomarker	[255]
RHOH	OT1J9SEB	Disputed	Biomarker	[256]
SERPINA9	OT0OIZH1	Disputed	Biomarker	[255]
ARAP3	OTUWZTH7	moderate	Genetic Variation	[257]
CCL13	OTNX0JD0	moderate	Biomarker	[84]
DDIT3	OTI8YKKE	moderate	Biomarker	[258]
DNER	OT2GH2E5	moderate	Biomarker	[259]
IRF2	OTAZRUW3	moderate	Altered Expression	[260]
KLHL1	OTAX6SAD	moderate	Biomarker	[261]
KMT2D	OTTVHCLY	moderate	Altered Expression	[262]
LBR	OT1HG3HG	moderate	Biomarker	[263]
MCTS1	OT7SAOJP	moderate	Biomarker	[75]
PARP14	OTFXJAKK	moderate	Biomarker	[264]
RAD50	OTYMU9G1	moderate	Biomarker	[265]
SLC7A4	OTAVC6QS	moderate	Altered Expression	[266]
SMUG1	OT2YIOCQ	moderate	Biomarker	[267]
SYCE1L	OTXU44F3	moderate	Biomarker	[261]
ACSBG1	OTM040MW	Strong	Biomarker	[268]
ADGRE2	OTUYJVYG	Strong	Altered Expression	[269]
ADGRE5	OTTSB84Q	Strong	Biomarker	[269]
AIP	OTDJ3OSV	Strong	Altered Expression	[270]
AMPD1	OTU17BCI	Strong	Biomarker	[271]
APCDD1	OTV9AD0L	Strong	Biomarker	[272]
ARHGEF5	OTUVGFT9	Strong	Biomarker	[273]
ARNT	OTMSIEZY	Strong	Altered Expression	[274]
ASCC2	OT3B204T	Strong	Biomarker	[186]
BAG6	OT4Z0S2U	Strong	Biomarker	[275]
BATF	OT9VSD2D	Strong	Biomarker	[276]
BCL2L10	OTYXQJ3I	Strong	Biomarker	[277]
BCL7A	OTYFUJTP	Strong	Genetic Variation	[278]
BCLAF1	OT7T8H6A	Strong	Biomarker	[279]
BIK	OTTH1T3D	Strong	Genetic Variation	[280]
BLNK	OTSSPF6F	Strong	Biomarker	[281]
BTG2	OTZF6K1H	Strong	Genetic Variation	[282]
BTRC	OT2EZDGR	Strong	Biomarker	[283]
BYSL	OTPTLZJT	Strong	Biomarker	[284]
C1QA	OT6XKVVA	Strong	Genetic Variation	[285]
C1RL	OTRTQWRV	Strong	Genetic Variation	[286]
CAMK1	OTRN55RE	Strong	Biomarker	[287]
CARD11	OTRCTLYC	Strong	Genetic Variation	[288]
CARD16	OT4NUHWB	Strong	Biomarker	[289]
CCAR1	OTUXLQZZ	Strong	Altered Expression	[198]
CCDC86	OT5YQ0R0	Strong	Biomarker	[290]
CCND2	OTDULQF9	Strong	Biomarker	[291]
CCNH	OTKDU3SR	Strong	Altered Expression	[292]
CCNT1	OTDYVGCP	Strong	Altered Expression	[293]
CCT4	OT5D452X	Strong	Biomarker	[145]
CD109	OTDADBM4	Strong	Biomarker	[294]
CD247	OT45FGUX	Strong	Biomarker	[208]
CD79A	OTOJC8DV	Strong	Biomarker	[295]
CD81	OTQFXNAZ	Strong	Biomarker	[296]
CDC42BPB	OTO6NT7Q	Strong	Genetic Variation	[297]
CHGB	OT7SAQT2	Strong	Altered Expression	[125]
CHRDL1	OTGMWVVA	Strong	Biomarker	[298]
CIB2	OT9ZJX1I	Strong	Posttranslational Modification	[299]
CIITA	OTRJNZFO	Strong	Genetic Variation	[300]
CKAP2	OTCLTC0J	Strong	Biomarker	[301]
CNOT6L	OTLBRR6Q	Strong	Biomarker	[302]
CNRIP1	OTXPWJ56	Strong	Biomarker	[303]
COMMD1	OT7WUD5R	Strong	Biomarker	[304]
CORO1A	OTVAZOHC	Strong	Biomarker	[305]
CSNK2B	OT2WW7R1	Strong	Altered Expression	[306]
CUL4B	OT2QX4DO	Strong	Altered Expression	[307]
CYBA	OT16N9ZO	Strong	Genetic Variation	[141]
D2HGDH	OTLHXW69	Strong	Genetic Variation	[308]
DAP	OT5YLL7E	Strong	Genetic Variation	[309]
DAPK1	OTNCNUCO	Strong	Posttranslational Modification	[310]
DAXX	OTX6O7PL	Strong	Biomarker	[311]
DEFB126	OT9NHGQE	Strong	Biomarker	[166]
DOCK2	OTZTS3PA	Strong	Biomarker	[312]
DTX3L	OTCCO2QZ	Strong	Biomarker	[313]
DUSP4	OT6WAO12	Strong	Biomarker	[314]
DVL3	OTPRROHJ	Strong	Genetic Variation	[306]
EFNA5	OTOH4DRR	Strong	Biomarker	[315]
EFNB2	OT0DCUOM	Strong	Altered Expression	[185]
EFS	OT06O7XL	Strong	Genetic Variation	[316]
EGR3	OTGPJIRA	Strong	Biomarker	[317]
EIF4A1	OTMTBX6N	Strong	Altered Expression	[318]
EIF4A2	OT08H03R	Strong	Altered Expression	[318]
EIF4B	OTE8TXA8	Strong	Biomarker	[319]
EIF4E3	OTTWVS2R	Strong	Altered Expression	[169]
EIF4G3	OTZCRXLJ	Strong	Altered Expression	[320]
ELL3	OTALC1YD	Strong	Altered Expression	[321]
ERCC2	OT1C8HQ4	Strong	Genetic Variation	[322]
ERCC5	OTQAKFJM	Strong	Biomarker	[311]
ETFA	OTXX61VZ	Strong	Biomarker	[323]
ETV5	OTE2OBM4	Strong	Biomarker	[324]
EXOC2	OT5QG1WG	Strong	Genetic Variation	[325]
FABP7	OTRE2H4G	Strong	Altered Expression	[326]
FBP1	OTQBANEP	Strong	Altered Expression	[327]
FCRL4	OT3DVTRV	Strong	Altered Expression	[328]
FCRLA	OT6MK4M1	Strong	Altered Expression	[329]
FOXK1	OTLZGS7J	Strong	Biomarker	[302]
FOXN3	OTOJYJZP	Strong	Biomarker	[330]
FOXO4	OT90X9LN	Strong	Biomarker	[331]
GCSAM	OTZNOPYK	Strong	Biomarker	[332]
GLIS2	OTOUUV1X	Strong	Biomarker	[333]
GMCL1	OTRZHUFV	Strong	Biomarker	[334]
GNA12	OT3IRZH3	Strong	Biomarker	[335]
GNA13	OTVDL515	Strong	Altered Expression	[205]
GPX4	OTRAFFX2	Strong	Altered Expression	[336]
GTF2H4	OTPD1DIU	Strong	Biomarker	[70]
GUCA1B	OT85S0J3	Strong	Biomarker	[337]
HELLS	OTVVV668	Strong	Biomarker	[338]
HIP1R	OTIPKEJC	Strong	Altered Expression	[339]
HLX	OT7DTH46	Strong	Altered Expression	[333]
HSPH1	OTVRR73T	Strong	Altered Expression	[340]
IBTK	OTB2GM4G	Strong	Biomarker	[341]
ID3	OTUULW5Z	Strong	Altered Expression	[342]
IL1RAPL1	OTW3T4B2	Strong	Biomarker	[343]
IL34	OTZ15VVK	Strong	Altered Expression	[344]
ILDR1	OTQK8XLK	Strong	Genetic Variation	[118]
ISL1	OTVNVKAX	Strong	Biomarker	[345]
KDM2B	OTDMCVW7	Strong	Biomarker	[346]
KDSR	OTCIES3H	Strong	Altered Expression	[347]
KIF2A	OT2WQ6QD	Strong	Altered Expression	[348]
KLHDC8B	OTKP6LCR	Strong	Biomarker	[298]
KMT2B	OTMMAZQX	Strong	Genetic Variation	[177]
LGALS13	OTEV3DD7	Strong	Biomarker	[349]
LIG4	OT40DNXU	Strong	Biomarker	[350]
LMNB1	OT100T3P	Strong	Biomarker	[351]
LMO3	OTR7AJHN	Strong	Biomarker	[352]
LPP	OT6TU8SE	Strong	Genetic Variation	[353]
LYPD4	OTYNO8BS	Strong	Genetic Variation	[354]
MAD2L1	OTXNGZCG	Strong	Altered Expression	[236]
MAD2L2	OT24ZO59	Strong	Biomarker	[355]
MAL	OTBM30SW	Strong	Biomarker	[356]
MARCHF8	OTH7PNN2	Strong	Altered Expression	[357]
MDN1	OTNBSPTW	Strong	Genetic Variation	[358]
MEF2B	OT880SE6	Strong	Altered Expression	[359]
MIB1	OT5C404P	Strong	Biomarker	[226]
MLXIP	OT30UNI7	Strong	Altered Expression	[357]
MORC1	OTCCJKFN	Strong	Altered Expression	[360]
MORC4	OTJBEHNE	Strong	Biomarker	[360]
MPIG6B	OTVNKQWA	Strong	Genetic Variation	[361]
MRPL58	OTPTWLZY	Strong	Biomarker	[362]
MSN	OTZJ4J6G	Strong	Biomarker	[324]
MTSS1	OT5DTDO2	Strong	Biomarker	[363]
MXD1	OTS5CTHX	Strong	Biomarker	[271]
MXI1	OTUQ9E0D	Strong	Altered Expression	[236]
MYLIP	OTL0PFGV	Strong	Altered Expression	[357]
MZB1	OT071TET	Strong	Altered Expression	[364]
NAPSA	OT6F8IAL	Strong	Altered Expression	[365]
NCOA1	OTLIUJQD	Strong	Genetic Variation	[325]
NCOR1	OT04XNOU	Strong	Biomarker	[366]
NCOR2	OTY917X0	Strong	Biomarker	[366]
NCR2	OT2H13BX	Strong	Altered Expression	[227]
NEDD4L	OT1B19RU	Strong	Biomarker	[367]
NFATC1	OT4TMERS	Strong	Biomarker	[368]
NFE2L1	OT1QHOS2	Strong	Biomarker	[369]
NKX6-3	OTAMUC7H	Strong	Altered Expression	[370]
NOL3	OT1K0L0D	Strong	Altered Expression	[371]
NPM3	OTIAM1A3	Strong	Altered Expression	[372]
NR2C2	OTDZWVOJ	Strong	Altered Expression	[163]
NRF1	OTOXWNV8	Strong	Biomarker	[369]
NUTM1	OTONYC08	Strong	Biomarker	[373]
OAS3	OT6E5FYS	Strong	Biomarker	[186]
OGT	OT1Z1ZXE	Strong	Biomarker	[374]
PARP9	OT7K4494	Strong	Biomarker	[375]
PATZ1	OT0X9WGR	Strong	Biomarker	[376]
PCDH10	OT2GIT0E	Strong	Posttranslational Modification	[377]
PER3	OTVKYVJA	Strong	Genetic Variation	[378]
PHB2	OTCAX3AW	Strong	Biomarker	[233]
PIAS2	OTJLSC3V	Strong	Genetic Variation	[379]
PICALM	OTQVRPMQ	Strong	Biomarker	[380]
PLAGL1	OTZAO900	Strong	Altered Expression	[381]
PLCG2	OTGVC9MY	Strong	Biomarker	[382]
PMAIP1	OTXEE550	Strong	Biomarker	[383]
POLD1	OTWO4UCJ	Strong	Biomarker	[64]
POU2AF1	OTOO6WHL	Strong	Altered Expression	[384]
PPA1	OTHZK1QB	Strong	Biomarker	[385]
PPP2R5E	OT8GPFT5	Strong	Altered Expression	[386]
PRDX6	OTS8KC8A	Strong	Altered Expression	[387]
PRKAG3	OTS1A2VE	Strong	Biomarker	[388]
PTMS	OT9PS4Q0	Strong	Altered Expression	[306]
PTPRD	OTZPJ3GX	Strong	Biomarker	[389]
PTPRO	OTFLKWOY	Strong	Altered Expression	[386]
RAD23B	OT0PGOG3	Strong	Biomarker	[142]
RANGAP1	OTZGD3LJ	Strong	Biomarker	[390]
RAPH1	OTMQXW7S	Strong	Biomarker	[268]
RASGEF1A	OT88HCDY	Strong	Genetic Variation	[391]
RASGRP4	OT15PWN4	Strong	Altered Expression	[392]
RBL1	OTDEBFYC	Strong	Biomarker	[393]
RCOR1	OTREADPC	Strong	Altered Expression	[394]
RDX	OTNSYUN6	Strong	Biomarker	[324]
RELB	OTU3QYEF	Strong	Biomarker	[395]
RFC1	OT3L5PK3	Strong	Posttranslational Modification	[203]
RFXANK	OTDX1026	Strong	Biomarker	[396]
RGS1	OTGXJYMG	Strong	Altered Expression	[397]
RMDN1	OTE1NB6U	Strong	Altered Expression	[398]
RPL23	OTXI1YLM	Strong	Altered Expression	[140]
RPS20	OTI8052R	Strong	Genetic Variation	[399]
RPS6	OTT4D1LN	Strong	Altered Expression	[400]
RREB1	OT62460U	Strong	Altered Expression	[126]
SH2D1A	OTLU49I5	Strong	Biomarker	[108]
SH3BP5	OTOOEGUJ	Strong	Altered Expression	[352]
SIAH1	OT29A838	Strong	Altered Expression	[401]
SMAD5	OTQNSVCQ	Strong	Biomarker	[402]
SMC1A	OT9ZMRK9	Strong	Biomarker	[302]
SMURF2	OT3TRVL7	Strong	Biomarker	[403]
SND1	OTT734JN	Strong	Biomarker	[186]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[404]
SPART	OTIVOS2I	Strong	Posttranslational Modification	[310]
SPI1	OTVCA1D0	Strong	Biomarker	[405]
SPOP	OTP0107S	Strong	Genetic Variation	[148]
SPRR1A	OTJMI34A	Strong	Altered Expression	[406]
SRM	OT4N5MDP	Strong	Biomarker	[407]
SSBP2	OTYG1G80	Strong	Altered Expression	[408]
SYBU	OT3FQV7N	Strong	Altered Expression	[398]
SYN2	OTK0DEGH	Strong	Biomarker	[352]
TAP2	OTWSYFI7	Strong	Altered Expression	[409]
TBC1D9	OTSSCTB5	Strong	Biomarker	[261]
TES	OTL8PP6V	Strong	Biomarker	[360]
TFF3	OTJJDRTU	Strong	Altered Expression	[410]
TIMELESS	OTD8DCBJ	Strong	Biomarker	[273]
TLX1	OTVN0MNW	Strong	Biomarker	[411]
TNIP1	OTRAOTEW	Strong	Biomarker	[412]
TRAF3	OT5TQBGV	Strong	Altered Expression	[413]
TSPAN33	OTH6C0WU	Strong	Altered Expression	[414]
ANP32B	OT3SQMLU	Definitive	Biomarker	[415]
ARID1A	OTRWDV3P	Definitive	Genetic Variation	[177]
BCR	OTCN76C1	Definitive	Biomarker	[416]
CUX1	OTU1LCNJ	Definitive	Biomarker	[186]
KALRN	OT8WRCBH	Definitive	Genetic Variation	[240]
LYPD5	OTGP7UKA	Definitive	Altered Expression	[91]
MCAT	OTH07FIW	Definitive	Biomarker	[75]
MIXL1	OT584VOQ	Definitive	Altered Expression	[417]
MTX1	OTLSDNZO	Definitive	Biomarker	[418]
NCOA5	OTOGWTWB	Definitive	Genetic Variation	[240]
POU2F2	OTPV0J0C	Definitive	Altered Expression	[230]
SART3	OTC1AM7S	Definitive	Biomarker	[186]
SOX11	OT4LG7LA	Definitive	Biomarker	[419]
SPIB	OTO4YKYI	Definitive	Altered Expression	[405]
TLE1	OT50MRZ1	Definitive	Posttranslational Modification	[420]
TNPO2	OTGHFQAV	Definitive	Genetic Variation	[240]
------------------------------------------------------------------------------------


⏷ Show the Full List of 264 DOT(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
3	ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
4	ClinicalTrials.gov (NCT02132624) CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
5	ClinicalTrials.gov (NCT01874288) Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL. U.S. National Institutes of Health.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7889).
7	ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL).
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	ClinicalTrials.gov (NCT02519816) Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD.
10	ClinicalTrials.gov (NCT03598179) XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
11	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
12	ClinicalTrials.gov (NCT03050190) A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
13	ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
14	ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
15	ClinicalTrials.gov (NCT02842138) Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
16	ClinicalTrials.gov (NCT03366324) Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
17	ClinicalTrials.gov (NCT02933320) BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia. U.S. National Institutes of Health.
18	ClinicalTrials.gov (NCT02965157) Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
19	ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
20	ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
21	ClinicalTrials.gov (NCT03146533) CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
22	ClinicalTrials.gov (NCT03118180) CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
23	ClinicalTrials.gov (NCT02794961) CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies
24	ClinicalTrials.gov (NCT03997968) A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors. U.S. National Institutes of Health.
25	ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
26	ClinicalTrials.gov (NCT03166878) A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
27	ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
28	ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
29	ClinicalTrials.gov (NCT04282018) Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab. U.S. National Institutes of Health.
30	ClinicalTrials.gov (NCT05294731) A Phase 1, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies. U.S.National Institutes of Health.
31	ClinicalTrials.gov (NCT03101709) The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
32	ClinicalTrials.gov (NCT04156243) CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies. U.S. National Institutes of Health.
33	ClinicalTrials.gov (NCT03559439) CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
34	ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
35	ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia
36	ClinicalTrials.gov (NCT03576807) The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
37	ClinicalTrials.gov (NCT04156178) CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies. U.S. National Institutes of Health.
38	ClinicalTrials.gov (NCT01561911) A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment. U.S. National Institutes of Health.
39	ClinicalTrials.gov (NCT04035434) A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON). U.S. National Institutes of Health.
40	ClinicalTrials.gov (NCT03642496) The Clinical Study of Structurally Optimized ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies. U.S.National Institutes of Health.
41	ClinicalTrials.gov (NCT04014894) Safety and Efficiency Study of ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma. U.S.National Institutes of Health.
42	ClinicalTrials.gov (NCT03841110) FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
43	ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
44	ClinicalTrials.gov (NCT03383952) A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
45	ClinicalTrials.gov (NCT04989803) A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma. U.S.National Institutes of Health.
46	Clinical pipeline report, company report or official report of Kuur Therapeutics.
47	ClinicalTrials.gov (NCT01659255) Phase I Study of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory NHL and CLL. U.S. National Institutes of Health.
48	ClinicalTrials.gov (NCT03281551) Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
49	ClinicalTrials.gov (NCT03804996) Study of TG-1801 in Subjects With B-Cell Lymphoma. U.S. National Institutes of Health.
50	ClinicalTrials.gov (NCT04594642) A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
51	ClinicalTrials.gov (NCT03682796) Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma. U.S. National Institutes of Health.
52	ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
53	ClinicalTrials.gov (NCT02813837) Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
54	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007687)
55	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010265)
56	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
57	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011874)
58	Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10131-6.
59	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
60	Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.Leuk Lymphoma. 2018 Jun;59(6):1375-1383. doi: 10.1080/10428194.2017.1387912. Epub 2017 Oct 11.
61	Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.J Immunother. 2020 Jan;43(1):32-37. doi: 10.1097/CJI.0000000000000284.
62	A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.Blood. 2005 Nov 15;106(10):3594-601. doi: 10.1182/blood-2005-02-0487. Epub 2005 Aug 4.
63	Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.Cancer Sci. 2020 Feb;111(2):749-759. doi: 10.1111/cas.14286. Epub 2020 Jan 13.
64	Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas.Int J Clin Exp Pathol. 2013;6(2):148-54. Epub 2013 Jan 15.
65	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.Blood Adv. 2019 Feb 12;3(3):360-369. doi: 10.1182/bloodadvances.2018027748.
66	CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015 Aug 6;126(6):779-89.
67	FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease.Blood. 2016 Aug 4;128(5):660-6. doi: 10.1182/blood-2015-11-684357. Epub 2016 May 10.
68	Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.Oncotarget. 2017 Jul 25;8(30):49757-49772. doi: 10.18632/oncotarget.17693.
69	LAMP1 Overexpression Predicts for Poor Prognosis in Diffuse Large B-cell Lymphoma.Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):749-754. doi: 10.1016/j.clml.2018.07.288. Epub 2018 Aug 3.
70	Frequent downregulation of BTB and CNC homology 2 expression in Epstein-Barr virus-positive diffuse large B-cell lymphoma.Cancer Sci. 2017 May;108(5):1071-1079. doi: 10.1111/cas.13213. Epub 2017 Apr 24.
71	Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data.Pharmacogenet Genomics. 2015 Jan;25(1):1-7. doi: 10.1097/FPC.0000000000000097.
72	Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.Exp Hematol. 2018 Mar;59:72-81.e2. doi: 10.1016/j.exphem.2017.12.006. Epub 2017 Dec 26.
73	ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.Biofactors. 2019 May;45(3):416-426. doi: 10.1002/biof.1498. Epub 2019 Feb 24.
74	Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.Leukemia. 2016 Apr;30(4):844-53. doi: 10.1038/leu.2015.328. Epub 2015 Dec 10.
75	Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.Cell Oncol (Dordr). 2019 Jun;42(3):303-318. doi: 10.1007/s13402-019-00426-2. Epub 2019 Feb 21.
76	The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21).J Pathol. 2017 Feb;241(3):420-433. doi: 10.1002/path.4852. Epub 2016 Dec 29.
77	Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.Mod Pathol. 2009 Mar;22(3):476-87. doi: 10.1038/modpathol.2008.207. Epub 2009 Jan 9.
78	Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma.Leuk Res. 2010 Jan;34(1):50-4. doi: 10.1016/j.leukres.2009.06.028. Epub 2009 Jul 18.
79	Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease.Leuk Lymphoma. 2013 Jun;54(6):1212-20. doi: 10.3109/10428194.2012.742522. Epub 2012 Nov 23.
80	Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry.Leuk Lymphoma. 2014 Nov;55(11):2592-6. doi: 10.3109/10428194.2013.879714. Epub 2014 Mar 3.
81	ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.Oncogene. 2011 Dec 8;30(49):4874-86. doi: 10.1038/onc.2011.195. Epub 2011 May 30.
82	AID and TET2 co-operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma.Clin Exp Immunol. 2019 Feb;195(2):190-201. doi: 10.1111/cei.13227. Epub 2018 Nov 13.
83	Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.J Exp Clin Cancer Res. 2019 Feb 18;38(1):86. doi: 10.1186/s13046-019-1076-4.
84	Single-nucleotide polymorphisms in genes encoding for CC chemokines were not associated with the risk of non-Hodgkin lymphoma.Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1332-5. doi: 10.1158/1055-9965.EPI-13-0328. Epub 2013 May 2.
85	Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.Cell Chem Biol. 2020 Jan 16;27(1):47-56.e15. doi: 10.1016/j.chembiol.2019.11.006. Epub 2019 Dec 9.
86	HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.Leukemia. 2018 Mar;32(3):703-711. doi: 10.1038/leu.2017.299. Epub 2017 Sep 28.
87	Gene expression meta-analysis reveals immune response convergence on the IFN-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma.Genome Med. 2015 Sep 11;7(1):96. doi: 10.1186/s13073-015-0218-3.
88	A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.Biochim Biophys Acta. 2014 Oct;1843(10):2240-52. doi: 10.1016/j.bbamcr.2014.04.017. Epub 2014 Apr 21.
89	LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.Cancer Cell. 2019 Sep 16;36(3):237-249.e6. doi: 10.1016/j.ccell.2019.07.007. Epub 2019 Aug 22.
90	Targeted inhibition of PI3K/ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.Blood. 2019 Jan 3;133(1):70-80. doi: 10.1182/blood-2018-08-872465. Epub 2018 Oct 15.
91	Identification of Pax5 as a target of MTA1 in B-cell lymphomas.Cancer Res. 2007 Aug 1;67(15):7132-8. doi: 10.1158/0008-5472.CAN-07-0750.
92	Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression.Cell Cycle. 2010 Feb 1;9(3):557-63. doi: 10.4161/cc.9.3.10554.
93	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.Blood. 2011 Nov 17;118(20):5517-27. doi: 10.1182/blood-2011-03-344374. Epub 2011 Sep 21.
94	CD148 and CD27 are expressed in B cell lymphomas derived from both memory and nave B cells.Leuk Lymphoma. 2002 Sep;43(9):1855-8. doi: 10.1080/1042819021000006385.
95	Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.Asian Pac J Cancer Prev. 2012;13(7):3037-46. doi: 10.7314/apjcp.2012.13.7.3037.
96	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.Leukemia. 2019 Oct;33(10):2416-2428. doi: 10.1038/s41375-019-0442-8. Epub 2019 Mar 14.
97	Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biology.Cancer Lett. 2018 Nov 1;436:149-158. doi: 10.1016/j.canlet.2018.08.020. Epub 2018 Aug 27.
98	Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5'-RACE and LA - PCR analyses of biopsy samples.Oncogene. 1999 Dec 23;18(56):7994-9. doi: 10.1038/sj.onc.1203293.
99	The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients.Hematol Oncol. 2017 Mar;35(1):87-93. doi: 10.1002/hon.2245. Epub 2015 Jul 14.
100	Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma.Cancer Sci. 2006 Jun;97(6):499-504. doi: 10.1111/j.1349-7006.2006.00209.x.
101	BCL-W has a fundamental role in B cell survival and lymphomagenesis.J Clin Invest. 2017 Feb 1;127(2):635-650. doi: 10.1172/JCI89486. Epub 2017 Jan 17.
102	MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.Am J Surg Pathol. 2017 Apr;41(4):541-549. doi: 10.1097/PAS.0000000000000799.
103	Promoter hypermethylation of the bone morphogenetic protein-6 gene in malignant lymphoma.Clin Cancer Res. 2007 Jun 15;13(12):3528-35. doi: 10.1158/1078-0432.CCR-06-2766.
104	Identification of B-cell translocation gene 1-controlled gene networks in diffuse large B-cell lymphoma: A study based on bioinformatics analysis.Oncol Lett. 2019 Mar;17(3):2825-2835. doi: 10.3892/ol.2019.9900. Epub 2019 Jan 8.
105	BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints.Exp Hematol. 2018 Apr;60:47-56.e1. doi: 10.1016/j.exphem.2018.01.003. Epub 2018 Feb 3.
106	L-Type Cav 1.2 Calcium Channel--1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma.Clin Cancer Res. 2019 Jul 1;25(13):4168-4178. doi: 10.1158/1078-0432.CCR-18-2146. Epub 2019 Mar 1.
107	NFAT1 transcription factor regulates cell cycle progression and cyclin E expression in B lymphocytes.Cell Cycle. 2016 Sep;15(17):2346-59. doi: 10.1080/15384101.2016.1203485. Epub 2016 Jul 11.
108	Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.Mol Cancer Ther. 2005 Dec;4(12):1867-79. doi: 10.1158/1535-7163.MCT-05-0146.
109	Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.BMC Cancer. 2019 Nov 6;19(1):1049. doi: 10.1186/s12885-019-6208-x.
110	Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.J Immunother Cancer. 2019 Nov 21;7(1):315. doi: 10.1186/s40425-019-0790-y.
111	Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma.Oncotarget. 2015 Oct 13;6(31):31191-202. doi: 10.18632/oncotarget.5152.
112	Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.Cytometry B Clin Cytom. 2019 Sep;96(5):368-374. doi: 10.1002/cyto.b.21770. Epub 2019 Feb 7.
113	Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma.J Pathol. 2019 Jun;248(2):142-154. doi: 10.1002/path.5237. Epub 2019 Mar 22.
114	Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.Int J Med Sci. 2019 Apr 20;16(4):556-566. doi: 10.7150/ijms.27610. eCollection 2019.
115	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.Invest New Drugs. 2019 Apr;37(2):297-306. doi: 10.1007/s10637-018-0655-0. Epub 2018 Aug 22.
116	Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.Am J Surg Pathol. 2020 Apr;44(4):444-455. doi: 10.1097/PAS.0000000000001386.
117	Anaplastic large cell lymphomas: a study of 75 pediatric patients.Pediatr Dev Pathol. 2007 May-Jun;10(3):181-91. doi: 10.2350/06-04-0082.1.
118	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways.Hum Mol Genet. 2020 Jan 1;29(1):70-79. doi: 10.1093/hmg/ddz228.
119	The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.Br J Cancer. 2019 Jun;120(12):1137-1146. doi: 10.1038/s41416-019-0471-0. Epub 2019 May 15.
120	Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.Oncotarget. 2015 Mar 30;6(9):6553-69. doi: 10.18632/oncotarget.2720.
121	Effects of CDC7 gene silencing and Rituximab on apoptosis in diffuse large B cell lymphoma cells.J Cancer Res Clin Oncol. 2012 Dec;138(12):2027-34. doi: 10.1007/s00432-012-1283-2. Epub 2012 Jul 18.
122	Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas.Cell Cycle. 2007 Dec 1;6(23):2982-9. doi: 10.4161/cc.6.23.4994.
123	Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling.BMC Med Genomics. 2011 Mar 31;4:27. doi: 10.1186/1755-8794-4-27.
124	Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.Blood Adv. 2019 Jan 8;3(1):51-62. doi: 10.1182/bloodadvances.2018026880.
125	Dysregulated expressions of PTEN, NF-B, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia.Am J Transl Res. 2019 Feb 15;11(2):1092-1101. eCollection 2019.
126	Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma.Mol Cancer Res. 2019 Feb;17(2):567-582. doi: 10.1158/1541-7786.MCR-18-0582. Epub 2018 Oct 24.
127	Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.Oncotarget. 2015 Jun 20;6(17):14796-813. doi: 10.18632/oncotarget.4193.
128	Clinical significance of co-expression of CD21 and LFA-1 in B-cell lymphoma.Int J Hematol. 2009 May;89(4):497-507. doi: 10.1007/s12185-009-0303-8. Epub 2009 Apr 11.
129	Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.Immunity. 2019 Sep 17;51(3):535-547.e9. doi: 10.1016/j.immuni.2019.08.006. Epub 2019 Sep 10.
130	Integrated analysis of genomewide gene expression and DNA methylation microarray of diffuse large Bcell lymphoma with TET mutations.Mol Med Rep. 2017 Oct;16(4):3777-3782. doi: 10.3892/mmr.2017.7058. Epub 2017 Jul 21.
131	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.Haematologica. 2020 Mar;105(3):741-753. doi: 10.3324/haematol.2018.211490. Epub 2019 Jun 27.
132	Characterization of an adenosine deaminase-deficient human histiocytic lymphoma cell line (DHL-9) and selection of mutants deficient in adenosir kinase and deoxycytidine kinase.Cancer Res. 1983 Jun;43(6):2606-10.
133	Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.Blood. 2020 Feb 27;135(9):597-609. doi: 10.1182/blood.2019002121.
134	Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma.PLoS One. 2011;6(9):e24617. doi: 10.1371/journal.pone.0024617. Epub 2011 Sep 8.
135	Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.Blood. 2018 May 10;131(19):2125-2137. doi: 10.1182/blood-2017-08-804344. Epub 2018 Mar 23.
136	The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.Haematologica. 2009 Sep;94(9):1307-11. doi: 10.3324/haematol.2009.008045.
137	Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival.Blood. 2016 Sep 22;128(12):1578-89. doi: 10.1182/blood-2016-02-702530. Epub 2016 Jun 23.
138	Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.Biomed Pharmacother. 2018 Oct;106:267-274. doi: 10.1016/j.biopha.2018.06.093. Epub 2018 Jun 28.
139	The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.Cytometry B Clin Cytom. 2018 May;94(3):451-458. doi: 10.1002/cyto.b.21533. Epub 2017 May 24.
140	A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.PLoS One. 2019 Oct 11;14(10):e0223260. doi: 10.1371/journal.pone.0223260. eCollection 2019.
141	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.Leukemia. 2009 Jun;23(6):1118-26. doi: 10.1038/leu.2008.398. Epub 2009 Jan 29.
142	Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.J Pathol. 2018 Oct;246(2):141-153. doi: 10.1002/path.5108. Epub 2018 Aug 20.
143	Glycolytic enzyme hexokinase II is a putative therapeutic target in B-cell malignant lymphoma.Exp Hematol. 2019 Oct;78:46-55.e3. doi: 10.1016/j.exphem.2019.09.023. Epub 2019 Sep 24.
144	The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.Leuk Lymphoma. 2019 Dec;60(12):2899-2908. doi: 10.1080/10428194.2019.1617858. Epub 2019 Jun 19.
145	Repositioning of Difluorinated Propanediones as Inhibitors of Histone Methyltransferases and their Biological Evaluation in Human Leukemic Cell Lines.Anticancer Agents Med Chem. 2018;18(13):1892-1899. doi: 10.2174/1871520618666180404125721.
146	IL10 receptor is a novel therapeutic target in DLBCLs.Leukemia. 2015 Aug;29(8):1684-94. doi: 10.1038/leu.2015.57. Epub 2015 Mar 3.
147	Polymorphism in interleukin 21 gene is associated with decreased susceptibility to diffuse large B cell lymphoma.Tumour Biol. 2014 Nov;35(11):11295-300. doi: 10.1007/s13277-014-2440-9. Epub 2014 Aug 14.
148	CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-B signaling.Leukemia. 2020 May;34(5):1305-1314. doi: 10.1038/s41375-019-0661-z. Epub 2019 Nov 27.
149	Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin's Lymphoma Risk and Survival.PLoS One. 2015 Oct 8;10(10):e0139329. doi: 10.1371/journal.pone.0139329. eCollection 2015.
150	Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas.EMBO Mol Med. 2009 Aug;1(5):288-95. doi: 10.1002/emmm.200900028.
151	Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88(L265P) Mutant Diffuse Large B Cell Lymphoma.J Med Chem. 2019 Nov 14;62(21):9918-9930. doi: 10.1021/acs.jmedchem.9b01346. Epub 2019 Nov 1.
152	Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.Haematologica. 2017 Feb;102(2):373-380. doi: 10.3324/haematol.2016.144964. Epub 2016 Oct 14.
153	Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma.J Immunol Methods. 2020 Mar;478:112714. doi: 10.1016/j.jim.2019.112714. Epub 2019 Nov 26.
154	Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.J Clin Med. 2019 Jul 22;8(7):1074. doi: 10.3390/jcm8071074.
155	The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas.Haematologica. 2006 Jun;91(6):772-80.
156	M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma.Sci Rep. 2016 Jul 28;6:30347. doi: 10.1038/srep30347.
157	The +252A/G polymorphism in the Lymphotoxin- gene and the risk of non-Hodgkin lymphoma: a meta-analysis.Eur Rev Med Pharmacol Sci. 2014;18(4):544-52.
158	In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study.Br J Haematol. 2020 Feb;188(3):413-423. doi: 10.1111/bjh.16176. Epub 2019 Aug 29.
159	DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.Cell Death Dis. 2017 Oct 12;8(10):e3111. doi: 10.1038/cddis.2017.472.
160	Post-translational Modifications of the CARMA1-BCL10-MALT1 Complex in Lymphocytes and Activated B-Cell Like Subtype of Diffuse Large B-Cell Lymphoma.Front Oncol. 2018 Nov 9;8:498. doi: 10.3389/fonc.2018.00498. eCollection 2018.
161	Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-B-inducing kinase while activating both canonical and alternative nuclear factor-B pathways.Blood. 2011 Jan 6;117(1):200-10. doi: 10.1182/blood-2010-06-290437. Epub 2010 Oct 1.
162	Chromosomal translocation t(11;18)(q21;q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma.J Clin Pathol. 2003 Jan;56(1):36-42. doi: 10.1136/jcp.56.1.36.
163	TAK1 is a druggable kinase for diffuse large B-cell lymphoma.Cell Biochem Funct. 2019 Apr;37(3):153-160. doi: 10.1002/cbf.3381. Epub 2019 Mar 24.
164	A novel fusion of the MALT1 gene and the microtubule-associated protein 4 (MAP4) gene occurs in diffuse large B-cell lymphoma.Genes Chromosomes Cancer. 2006 Sep;45(9):863-73. doi: 10.1002/gcc.20350.
165	Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7259-64. doi: 10.1073/pnas.1137463100. Epub 2003 May 19.
166	Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.Environ Mol Mutagen. 2013 Jan;54(1):72-7. doi: 10.1002/em.21739. Epub 2012 Oct 11.
167	Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.Blood Cancer J. 2019 Nov 18;9(12):87. doi: 10.1038/s41408-019-0249-x.
168	High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts.Lab Invest. 2002 Jul;82(7):893-901. doi: 10.1097/01.lab.0000020419.25365.c4.
169	MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.Nat Commun. 2014 Nov 18;5:5413. doi: 10.1038/ncomms6413.
170	Anticancer effect of quinacrine on diffuse large Bcell lymphoma via inhibition of MSI2NUMB signaling pathway.Mol Med Rep. 2018 Jan;17(1):522-530. doi: 10.3892/mmr.2017.7892. Epub 2017 Oct 26.
171	Deletion of dinucleotide repeat (Delta 14 allele) in the methylthioadenosine phosphorylase (MTAP) promoter and the allelotype of MTAP promoter in the Japanese population.Jpn J Cancer Res. 2002 Apr;93(4):369-73. doi: 10.1111/j.1349-7006.2002.tb01266.x.
172	Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.APMIS. 2011 Apr;119(4-5):296-303. doi: 10.1111/j.1600-0463.2011.02733.x. Epub 2011 Mar 25.
173	MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.Blood. 2010 Sep 2;116(9):1515-23. doi: 10.1182/blood-2010-03-272567. Epub 2010 Jun 4.
174	nm23-H1 protein expression and gene mutation in 150 patients with non-Hodgkin's lymphomas.J Korean Med Sci. 2006 Aug;21(4):645-51. doi: 10.3346/jkms.2006.21.4.645.
175	JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.Sci Rep. 2017 Aug 7;7(1):7433. doi: 10.1038/s41598-017-07964-5.
176	The truncate mutation of Notch2 enhances cell proliferation through activating the NF-B signal pathway in the diffuse large B-cell lymphomas.PLoS One. 2014 Oct 14;9(10):e108747. doi: 10.1371/journal.pone.0108747. eCollection 2014.
177	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.Mod Pathol. 2016 Jul;29(7):685-97. doi: 10.1038/modpathol.2016.79. Epub 2016 Apr 22.
178	Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation.J Neuropathol Exp Neurol. 2018 Apr 1;77(4):268-273. doi: 10.1093/jnen/nlx121.
179	PD-L1 and tumor-associated macrophages in de novo DLBCL.Blood Adv. 2019 Feb 26;3(4):531-540. doi: 10.1182/bloodadvances.2018020602.
180	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.Leukemia. 2019 Jul;33(7):1687-1699. doi: 10.1038/s41375-019-0380-5. Epub 2019 Jan 25.
181	Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K in Mature B-cell Malignancies.Clin Cancer Res. 2018 Mar 1;24(5):1103-1113. doi: 10.1158/1078-0432.CCR-17-2218. Epub 2017 Dec 15.
182	Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.Biochem Biophys Res Commun. 2019 Jan 15;508(3):825-831. doi: 10.1016/j.bbrc.2018.12.004. Epub 2018 Dec 7.
183	Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis.J Cell Mol Med. 2019 Nov;23(11):7395-7405. doi: 10.1111/jcmm.14601. Epub 2019 Sep 4.
184	Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.Int J Exp Pathol. 2019 Feb;100(1):32-40. doi: 10.1111/iep.12307. Epub 2019 Mar 25.
185	Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.Am J Surg Pathol. 2018 Jul;42(7):936-950. doi: 10.1097/PAS.0000000000001071.
186	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.Oncogene. 2017 Jul 20;36(29):4224-4232. doi: 10.1038/onc.2017.90. Epub 2017 Apr 3.
187	Diffuse large B cell lymphoma-derived extracellular vesicles educate macrophages to promote tumours progression by increasing PGC-1.Scand J Immunol. 2020 Feb;91(2):e12841. doi: 10.1111/sji.12841. Epub 2019 Dec 13.
188	Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.J Biol Chem. 2020 Jan 31;295(5):1165-1180. doi: 10.1074/jbc.RA119.008742. Epub 2019 Dec 10.
189	Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.Eur J Haematol. 2017 Jan;98(1):52-56. doi: 10.1111/ejh.12784. Epub 2016 Jul 12.
190	Atypical Epstein-Barr viral genomic structure in lymphoma tissue and lymphoid cell lines.Diagn Mol Pathol. 2013 Jun;22(2):91-101. doi: 10.1097/PDM.0b013e318273fb43.
191	5-Azacitidine induces demethylation of PTPL1 and inhibits growth in non-Hodgkin lymphoma.Int J Mol Med. 2015 Sep;36(3):698-704. doi: 10.3892/ijmm.2015.2269. Epub 2015 Jul 1.
192	T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.Mol Cell Biol. 2007 Mar;27(6):2166-79. doi: 10.1128/MCB.01234-06. Epub 2007 Jan 8.
193	Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL.Oncol Rep. 2016 Jan;35(1):139-46. doi: 10.3892/or.2015.4347. Epub 2015 Oct 26.
194	The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling.J Cell Sci. 2016 May 1;129(9):1775-80. doi: 10.1242/jcs.185025. Epub 2016 Mar 22.
195	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.Oncotarget. 2015 Sep 15;6(27):23157-80. doi: 10.18632/oncotarget.4319.
196	Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.Blood. 2008 Feb 1;111(3):1644-53. doi: 10.1182/blood-2007-05-088591. Epub 2007 Nov 19.
197	Mapping of the human RNASEL promoter and expression in cancer and normal cells.J Interferon Cytokine Res. 2005 Oct;25(10):595-603. doi: 10.1089/jir.2005.25.595.
198	Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.Cancer Chemother Pharmacol. 2011 Jun;67(6):1401-13. doi: 10.1007/s00280-010-1442-6. Epub 2010 Aug 31.
199	Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group.Ann Hematol. 2019 Dec;98(12):2815-2823. doi: 10.1007/s00277-019-03835-3. Epub 2019 Nov 12.
200	Amplification at 11q23 targets protein kinase SIK2 in diffuse large B-cell lymphoma.Leuk Lymphoma. 2010 May;51(5):881-91. doi: 10.3109/10428191003699878.
201	S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. J Pathol. 2008 Dec;216(4):483-94. doi: 10.1002/path.2433.
202	Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.Nat Commun. 2019 Feb 1;10(1):533. doi: 10.1038/s41467-018-08013-z.
203	Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.Eur J Haematol. 2008 Jan;80(1):61-6. doi: 10.1111/j.1600-0609.2007.00980.x. Epub 2007 Nov 19.
204	The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.Invest New Drugs. 2019 Jun;37(3):548-558. doi: 10.1007/s10637-019-00769-5. Epub 2019 Apr 26.
205	Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.Blood Adv. 2019 Oct 22;3(20):3020-3032. doi: 10.1182/bloodadvances.2019000210.
206	The impact of SOCS1 mutations in diffuse large B-cell lymphoma.Br J Haematol. 2019 Dec;187(5):627-637. doi: 10.1111/bjh.16147. Epub 2019 Aug 12.
207	Loss of TNFAIP3 enhances MYD88(L265P)-driven signaling in non-Hodgkin lymphoma.Blood Cancer J. 2018 Oct 9;8(10):97. doi: 10.1038/s41408-018-0130-3.
208	Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.Clin Immunol. 2014 Dec;155(2):160-75. doi: 10.1016/j.clim.2014.10.002. Epub 2014 Oct 16.
209	Clonal expanded TRA and TRB subfamily T cells in peripheral blood from patients with diffuse large B-cell lymphoma.Hematology. 2010 Apr;15(2):81-7. doi: 10.1179/102453310X12583347009856.
210	TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.Histopathology. 2017 Jul;71(1):98-111. doi: 10.1111/his.13204. Epub 2017 Apr 27.
211	UCH-L1 in DLBCL: marker or target?.Blood. 2016 Mar 24;127(12):1524-5. doi: 10.1182/blood-2016-01-689984.
212	Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death.Blood. 2012 Nov 29;120(23):4635-44. doi: 10.1182/blood-2012-06-438234. Epub 2012 Oct 12.
213	B7-H4 is highly expressed in aggressive Epstein-Barr virus positive diffuse large B-cell lymphoma and inhibits apoptosis through upregulating Erk1/2 and Akt signalling pathways.Infect Agent Cancer. 2019 Aug 8;14:20. doi: 10.1186/s13027-019-0234-9. eCollection 2019.
214	MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.Blood Adv. 2019 Apr 9;3(7):1185-1196. doi: 10.1182/bloodadvances.2018029660.
215	Polymorphisms in DNA repair pathway genes, body mass index, and risk of non-Hodgkin lymphoma.Am J Hematol. 2013 Jul;88(7):606-11. doi: 10.1002/ajh.23463. Epub 2013 May 30.
216	XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.J Hematol Oncol. 2017 Feb 14;10(1):47. doi: 10.1186/s13045-017-0412-4.
217	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.J Pathol. 2005 Mar;205(4):507-13. doi: 10.1002/path.1727.
218	New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).Br J Haematol. 2020 Mar;188(6):888-897. doi: 10.1111/bjh.16263. Epub 2019 Nov 28.
219	The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.Front Oncol. 2019 Nov 29;9:1301. doi: 10.3389/fonc.2019.01301. eCollection 2019.
220	Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.Oncotarget. 2016 Dec 13;7(50):83294-83307. doi: 10.18632/oncotarget.13065.
221	FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Hematol Oncol. 2017 Dec;35(4):447-455. doi: 10.1002/hon.2305. Epub 2016 Jun 10.
222	FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.Blood. 2016 Feb 11;127(6):739-48. doi: 10.1182/blood-2015-06-654111. Epub 2015 Nov 19.
223	Active IKK promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma.Blood. 2016 Feb 4;127(5):605-15. doi: 10.1182/blood-2015-07-658781. Epub 2015 Nov 24.
224	Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E498-E505. doi: 10.1073/pnas.1715118115. Epub 2018 Jan 2.
225	Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.Eur J Haematol. 2014;92(5):407-12. doi: 10.1111/ejh.12263. Epub 2014 Mar 10.
226	Primary thyroid lymphoma: A series from a tertiary care center in Northern India.J Cancer Res Ther. 2019 Jul-Sep;15(3):669-675. doi: 10.4103/jcrt.JCRT_135_17.
227	Modulation the expression of natural killer cell activating receptor (NKp44) in the peripheral blood of diffuse large B-cell lymphoma patients and the correlation with clinic pathological features.Clin Immunol. 2018 Mar;188:38-44. doi: 10.1016/j.clim.2017.12.003. Epub 2017 Dec 13.
228	Nek2 is a novel regulator of B cell development and immunological response.Biomed Res Int. 2014;2014:621082. doi: 10.1155/2014/621082. Epub 2014 Nov 17.
229	Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.Per Med. 2019 Jul;16(4):313-323. doi: 10.2217/pme-2018-0068. Epub 2019 Jul 23.
230	An unusual case of Epstein-Barr virus-positive large B-cell lymphoma lacking various B-cell markers.Diagn Pathol. 2017 Jan 31;12(1):15. doi: 10.1186/s13000-017-0606-7.
231	CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients.Open Med (Wars). 2018 Nov 27;13:605-609. doi: 10.1515/med-2018-0089. eCollection 2018.
232	New insights into redox homeostasis as a therapeutic target in B-cell malignancies.Curr Opin Hematol. 2017 Jul;24(4):393-401. doi: 10.1097/MOH.0000000000000351.
233	Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.J Exp Clin Cancer Res. 2019 Nov 4;38(1):450. doi: 10.1186/s13046-019-1440-4.
234	The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma.Sci Rep. 2019 Jun 13;9(1):8586. doi: 10.1038/s41598-019-44661-x.
235	Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin.Blood. 2018 Mar 22;131(12):1325-1336. doi: 10.1182/blood-2017-07-794875. Epub 2018 Feb 1.
236	Mad2 overexpression is associated with high cell proliferation and reduced disease-free survival in primary gastrointestinal diffuse large B-cell lymphoma.Hematology. 2016 Aug;21(7):399-403. doi: 10.1080/10245332.2015.1101970. Epub 2016 Mar 16.
237	Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.Exp Hematol. 2015 Jul;43(7):534-6. doi: 10.1016/j.exphem.2015.04.006. Epub 2015 Apr 27.
238	Design and synthesis of novel spirooxindole-indenoquinoxaline derivatives as novel tryptophanyl-tRNA synthetase inhibitors.Mol Divers. 2020 Nov;24(4):1043-1063. doi: 10.1007/s11030-019-10011-2. Epub 2019 Dec 13.
239	A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.Blood. 2018 Apr 19;131(16):1805-1808. doi: 10.1182/blood-2017-08-802561. Epub 2018 Jan 31.
240	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.Genet Epidemiol. 2019 Oct;43(7):844-863. doi: 10.1002/gepi.22242. Epub 2019 Aug 13.
241	Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas.Genes Chromosomes Cancer. 2016 Dec;55(12):932-943. doi: 10.1002/gcc.22391. Epub 2016 Jul 12.
242	The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.Cell. 2015 Apr 9;161(2):319-32. doi: 10.1016/j.cell.2015.02.043. Epub 2015 Apr 2.
243	Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma.Adv Hematol. 2012;2012:529572. doi: 10.1155/2012/529572. Epub 2012 Feb 26.
244	Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate (177)Lu-NNV003.Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2311-2321. doi: 10.1007/s00259-019-04417-1. Epub 2019 Jul 15.
245	FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-B to promote survival of human B cells.Blood. 2014 Nov 27;124(23):3431-40. doi: 10.1182/blood-2014-01-553412. Epub 2014 Sep 29.
246	Cooperative STAT/NF-B signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression.Nat Commun. 2018 Apr 17;9(1):1514. doi: 10.1038/s41467-018-03803-x.
247	Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma.Int J Hematol. 2017 Dec;106(6):794-800. doi: 10.1007/s12185-017-2315-0. Epub 2017 Sep 6.
248	Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.Korean J Intern Med. 2017 Mar;32(2):335-344. doi: 10.3904/kjim.2015.161. Epub 2016 Mar 11.
249	KLHL6 is a tumor suppressor gene in diffuse large B-cell lymphoma.Cell Cycle. 2019 Feb;18(3):249-256. doi: 10.1080/15384101.2019.1568765. Epub 2019 Jan 24.
250	A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.Br J Cancer. 2004 Jul 5;91(1):141-9. doi: 10.1038/sj.bjc.6601875.
251	Loss of PRDM11 promotes MYC-driven lymphomagenesis.Blood. 2015 Feb 19;125(8):1272-81. doi: 10.1182/blood-2014-03-560805. Epub 2014 Dec 12.
252	Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome.Leuk Lymphoma. 2002 Dec;43(12):2309-17. doi: 10.1080/1042819021000040017.
253	Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index.Blood. 2002 Oct 15;100(8):2950-6. doi: 10.1182/blood.V100.8.2950.
254	Compound Heterozygous DOCK8 Mutations in a Patient with B Lymphoblastic Leukemia and EBV-Associated Diffuse Large B Cell Lymphoma.J Clin Immunol. 2019 Aug;39(6):592-595. doi: 10.1007/s10875-019-00663-y. Epub 2019 Jul 2.
255	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.Clin Cancer Res. 2009 Sep 1;15(17):5494-502. doi: 10.1158/1078-0432.CCR-09-0113. Epub 2009 Aug 25.
256	Aberrant somatic hypermutations in thyroid lymphomas.Leuk Res. 2009 May;33(5):649-54. doi: 10.1016/j.leukres.2008.10.007. Epub 2008 Nov 18.
257	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.Nat Genet. 2014 Nov;46(11):1233-8. doi: 10.1038/ng.3105. Epub 2014 Sep 28.
258	Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.Leuk Lymphoma. 2019 Aug;60(8):1890-1898. doi: 10.1080/10428194.2018.1564823. Epub 2019 Jan 28.
259	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.Haematologica. 2019 Apr;104(4):778-788. doi: 10.3324/haematol.2017.180505. Epub 2018 Jun 28.
260	BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFN-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.J Cell Sci. 2013 May 1;126(Pt 9):1969-80. doi: 10.1242/jcs.118174. Epub 2013 Mar 13.
261	A p110-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-B.Int J Oncol. 2017 May;50(5):1711-1720. doi: 10.3892/ijo.2017.3923. Epub 2017 Mar 21.
262	Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.Nat Med. 2015 Oct;21(10):1190-8. doi: 10.1038/nm.3940. Epub 2015 Sep 14.
263	Glycosylation in lymphoma: Biology and glycotherapy.Pathol Int. 2019 Aug;69(8):441-449. doi: 10.1111/pin.12834. Epub 2019 Jul 17.
264	Research Progress on PARP14 as a Drug Target.Front Pharmacol. 2019 Mar 5;10:172. doi: 10.3389/fphar.2019.00172. eCollection 2019.
265	Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma.BMC Med Genet. 2009 Nov 16;10:117. doi: 10.1186/1471-2350-10-117.
266	Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome.Leukemia. 2004 Feb;18(2):326-30. doi: 10.1038/sj.leu.2403249.
267	Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art.Hematol Oncol. 2020 Feb;38(1):12-21. doi: 10.1002/hon.2676. Epub 2019 Nov 13.
268	Indolent T-cell lymphoproliferative disease with synchronous diffuse large B-cell lymphoma: A case report.Medicine (Baltimore). 2019 Apr;98(17):e15323. doi: 10.1097/MD.0000000000015323.
269	Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.BMC Cancer. 2019 Apr 5;19(1):322. doi: 10.1186/s12885-019-5537-0.
270	Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.Cell Rep. 2019 Apr 30;27(5):1461-1471.e4. doi: 10.1016/j.celrep.2019.04.014.
271	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.
272	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.Blood. 2015 Jun 11;125(24):3679-87. doi: 10.1182/blood-2015-03-635169. Epub 2015 Apr 17.
273	Expression of Tim-1 in primary CNS lymphoma.Cancer Med. 2016 Nov;5(11):3235-3245. doi: 10.1002/cam4.930. Epub 2016 Oct 5.
274	BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.Haematologica. 2015 Jun;100(6):801-9. doi: 10.3324/haematol.2014.120048. Epub 2015 Mar 13.
275	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.J Clin Invest. 2010 Dec 1;120(12):4569-82. doi: 10.1172/JCI42869. Epub 2010 Nov 1.
276	SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.Nucleic Acids Res. 2014 Jul;42(12):7591-610. doi: 10.1093/nar/gku451. Epub 2014 May 29.
277	Bcl-B expression in human epithelial and nonepithelial malignancies.Clin Cancer Res. 2008 May 15;14(10):3011-21. doi: 10.1158/1078-0432.CCR-07-1955.
278	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1259-70. doi: 10.1158/1055-9965.EPI-08-1037. Epub 2009 Mar 31.
279	Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.Cancer Biol Ther. 2018;19(9):825-834. doi: 10.1080/15384047.2018.1472188. Epub 2018 Jul 3.
280	Mutations of the BIK gene in human peripheral B-cell lymphomas.Genes Chromosomes Cancer. 2003 Sep;38(1):91-6. doi: 10.1002/gcc.10245.
281	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.Blood. 2013 Dec 19;122(26):4220-9. doi: 10.1182/blood-2012-12-473090. Epub 2013 Oct 29.
282	Genomic characterization of primary central nervous system lymphoma.Acta Neuropathol. 2016 Jun;131(6):865-75. doi: 10.1007/s00401-016-1536-2. Epub 2016 Jan 12.
283	-TrCP1 promotes cell proliferation via TNF-dependent NF-B activation in diffuse large B cell lymphoma.Cancer Biol Ther. 2020;21(3):241-247. doi: 10.1080/15384047.2019.1683332. Epub 2019 Nov 15.
284	Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma.Clin Cancer Res. 2005 Dec 1;11(23):8265-72. doi: 10.1158/1078-0432.CCR-05-1028.
285	Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.Intern Med J. 2012 Oct;42(10):1113-9. doi: 10.1111/j.1445-5994.2011.02587.x.
286	Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma.Environ Mol Mutagen. 2012 Mar;53(2):145-51. doi: 10.1002/em.21675. Epub 2011 Dec 15.
287	Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.Cancer Sci. 2003 Sep;94(9):774-81. doi: 10.1111/j.1349-7006.2003.tb01518.x.
288	MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):311-318. doi: 10.1097/PAI.0000000000000585.
289	Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma.J Transl Med. 2018 Dec 11;16(1):349. doi: 10.1186/s12967-018-1738-6.
290	Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med. 2013 Aug;5(8):1180-95. doi: 10.1002/emmm.201202034. Epub 2013 Jul 4.
291	Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels.J Exp Clin Cancer Res. 2019 Feb 12;38(1):73. doi: 10.1186/s13046-019-1081-7.
292	Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.Hum Pathol. 2008 Jun;39(6):885-94. doi: 10.1016/j.humpath.2007.10.014. Epub 2008 Apr 8.
293	EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.Haematologica. 2020 Apr;105(4):1021-1031. doi: 10.3324/haematol.2019.222935. Epub 2019 Jul 9.
294	CD109, a negative regulator of TGF- signaling, is a putative risk marker in diffuse large B-cell lymphoma.Int J Hematol. 2017 May;105(5):614-622. doi: 10.1007/s12185-016-2173-1. Epub 2016 Dec 28.
295	Blockade of oncogenic IB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70. doi: 10.1073/pnas.1411701111. Epub 2014 Jul 21.
296	Splenic large B-cell lymphoma in patients with hepatitis C virus infection.Hum Pathol. 2005 Aug;36(8):878-85. doi: 10.1016/j.humpath.2005.06.005.
297	Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility.J Hum Genet. 2011 Jun;56(6):436-9. doi: 10.1038/jhg.2011.35. Epub 2011 Apr 7.
298	Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types.Cancer Sci. 2017 Jun;108(6):1271-1280. doi: 10.1111/cas.13249. Epub 2017 May 23.
299	Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype.Blood. 2002 Oct 1;100(7):2572-7. doi: 10.1182/blood-2001-11-0026.
300	Recurrent genomic rearrangements in primary testicular lymphoma.J Pathol. 2015 Jun;236(2):136-41. doi: 10.1002/path.4522. Epub 2015 Mar 26.
301	Identification of a novel cDNA, encoding a cytoskeletal associated protein, differentially expressed in diffuse large B cell lymphomas.Oncogene. 1998 Sep 10;17(10):1245-51. doi: 10.1038/sj.onc.1202048.
302	Identification of potential key genes associated with diffuse large B-cell lymphoma based on microarray gene expression profiling.Neoplasma. 2017;64(6):824-833. doi: 10.4149/neo_2017_603.
303	Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma.Epigenetics. 2014 Mar;9(3):428-36. doi: 10.4161/epi.27554. Epub 2013 Dec 20.
304	Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.PLoS One. 2014 Mar 13;9(3):e91031. doi: 10.1371/journal.pone.0091031. eCollection 2014.
305	Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas.APMIS. 2009 Feb;117(2):87-94. doi: 10.1111/j.1600-0463.2008.00017.x.
306	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.Oncotarget. 2016 Dec 20;7(51):83987-84002. doi: 10.18632/oncotarget.9793.
307	CUL4B regulates autophagy via JNK signaling in diffuse large B-cell lymphoma.Cell Cycle. 2019 Feb;18(4):379-394. doi: 10.1080/15384101.2018.1560718. Epub 2019 Feb 1.
308	D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2.Nat Commun. 2015 Jul 16;6:7768. doi: 10.1038/ncomms8768.
309	Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma.Oncotarget. 2014 Oct 30;5(20):9798-810. doi: 10.18632/oncotarget.2394.
310	Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma.Leuk Res. 2017 Jun;57:89-96. doi: 10.1016/j.leukres.2017.02.012. Epub 2017 Mar 9.
311	A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma.Leukemia. 2014 May;28(5):1092-102. doi: 10.1038/leu.2013.295. Epub 2013 Oct 18.
312	DOCK2 regulates cell proliferation through Rac and ERK activation in B cell lymphoma.Biochem Biophys Res Commun. 2010 Apr 23;395(1):111-5. doi: 10.1016/j.bbrc.2010.03.148. Epub 2010 Mar 27.
313	HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.Oncotarget. 2015 Mar 10;6(7):4863-87. doi: 10.18632/oncotarget.3120.
314	DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma.J Exp Med. 2015 May 4;212(5):775-92. doi: 10.1084/jem.20141957. Epub 2015 Apr 6.
315	Screening of key genes associated with RCHOP immunochemotherapy and construction of a prognostic risk model in diffuse large Bcell lymphoma.Mol Med Rep. 2019 Oct;20(4):3679-3690. doi: 10.3892/mmr.2019.10627. Epub 2019 Aug 29.
316	The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis.Leuk Lymphoma. 2019 Aug;60(8):1958-1964. doi: 10.1080/10428194.2018.1564049. Epub 2019 Jan 28.
317	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?.Nutr Cancer. 2018 Oct;70(7):1088-1090. doi: 10.1080/01635581.2018.1502328. Epub 2018 Sep 20.
318	Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.Blood. 2014 Dec 11;124(25):3758-67. doi: 10.1182/blood-2014-07-589689. Epub 2014 Oct 15.
319	Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.Nat Commun. 2018 Feb 26;9(1):829. doi: 10.1038/s41467-018-03028-y.
320	Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development.PLoS Genet. 2014 Jan 30;10(1):e1004105. doi: 10.1371/journal.pgen.1004105. eCollection 2014 Jan.
321	Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.Mol Immunol. 2017 Nov;91:8-16. doi: 10.1016/j.molimm.2017.08.016. Epub 2017 Aug 31.
322	Association of ERCC2 Gene Polymorphisms with Susceptibility to Diffuse Large B-Cell Lymphoma.Med Sci Monit. 2018 Oct 3;24:7015-7022. doi: 10.12659/MSM.908813.
323	CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease.Blood. 1996 Apr 1;87(7):2905-17.
324	Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.Leukemia. 2015 Sep;29(9):1857-67. doi: 10.1038/leu.2015.86. Epub 2015 Mar 24.
325	Integrating understanding of epidemiology and genomics in B-cell non-Hodgkin lymphoma as a pathway to novel management strategies.Discov Med. 2016 Mar;21(115):181-8.
326	Distinct isoform of FABP7 revealed by screening for retroelement-activated genes in diffuse large B-cell lymphoma.Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3534-43. doi: 10.1073/pnas.1405507111. Epub 2014 Aug 11.
327	Expression of far upstream element binding protein1 in Bcell nonHodgkin lymphoma is correlated with tumor growth and celladhesion mediated drug resistance.Mol Med Rep. 2016 Oct;14(4):3759-68. doi: 10.3892/mmr.2016.5718. Epub 2016 Sep 6.
328	Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma.Hum Pathol. 2017 Jan;59:70-79. doi: 10.1016/j.humpath.2016.09.011. Epub 2016 Sep 22.
329	An unusual Fc receptor-related protein expressed in human centroblasts.Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3776-81. doi: 10.1073/pnas.022042699. Epub 2002 Mar 12.
330	FOXN3 is downregulated in osteosarcoma and transcriptionally regulates SIRT6, and suppresses migration and invasion in osteosarcoma.Oncol Rep. 2019 Feb;41(2):1404-1414. doi: 10.3892/or.2018.6878. Epub 2018 Nov 21.
331	FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma.Oncotarget. 2017 Jan 10;8(2):2466-2476. doi: 10.18632/oncotarget.13690.
332	miR-155 regulates HGAL expression and increases lymphoma cell motility.Blood. 2012 Jan 12;119(2):513-20. doi: 10.1182/blood-2011-08-370536. Epub 2011 Nov 16.
333	Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL.PLoS One. 2019 May 29;14(5):e0216898. doi: 10.1371/journal.pone.0216898. eCollection 2019.
334	1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma.EMBO Mol Med. 2010 May;2(5):159-71. doi: 10.1002/emmm.201000067.
335	Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.Carcinogenesis. 2017 Aug 1;38(8):812-820. doi: 10.1093/carcin/bgx061.
336	Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma.Lab Invest. 2018 May;98(5):609-619. doi: 10.1038/s41374-017-0008-1. Epub 2018 Feb 20.
337	Induction of leukemia cell differentiation and apoptosis by recombinant P48, a modulin derived from Mycoplasma fermentans.Biochem Biophys Res Commun. 2000 Mar 5;269(1):284-9. doi: 10.1006/bbrc.2000.2282.
338	Chromatin remodeling factor lymphoid-specific helicase links with Epstein-Barr virus associated the follicular germinal center B cell lymphomas.J Cancer Res Ther. 2019;15(2):350-357. doi: 10.4103/jcrt.JCRT_243_18.
339	FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.Oncotarget. 2016 Aug 16;7(33):52940-52956. doi: 10.18632/oncotarget.9507.
340	HSP110 sustains chronic NF-B signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.Blood. 2018 Aug 2;132(5):510-520. doi: 10.1182/blood-2017-12-819706. Epub 2018 Jun 5.
341	Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.Cancer Discov. 2017 Sep;7(9):940-942. doi: 10.1158/2159-8290.CD-17-0714.
342	A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome.Ann Oncol. 2013 Jan;24(1):193-201. doi: 10.1093/annonc/mds209. Epub 2012 Sep 11.
343	IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development.Cancer Immunol Res. 2019 Jun;7(6):874-885. doi: 10.1158/2326-6066.CIR-18-0698. Epub 2019 Apr 24.
344	Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma.Clin Transl Immunology. 2019 Aug 13;8(8):e1074. doi: 10.1002/cti2.1074. eCollection 2019.
345	A positive feedback regulation of ISL-1 in DLBCL but not in pancreatic -cells.Biochem Biophys Res Commun. 2014 Jul 4;449(3):295-300. doi: 10.1016/j.bbrc.2014.05.021. Epub 2014 May 15.
346	FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.Cell Death Dis. 2018 Jan 19;9(2):46. doi: 10.1038/s41419-017-0066-8.
347	Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome.Am J Clin Pathol. 2008 Dec;130(6):957-62. doi: 10.1309/AJCP12HIRWSRQLAN.
348	High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma.Ann Hematol. 2017 Sep;96(9):1485-1491. doi: 10.1007/s00277-017-3047-1. Epub 2017 Jun 14.
349	Regulatory roles of altered N- and O-glycosylation of CD45 in galectin-1-induced cell death in human diffuse large B cell lymphoma.Int J Oncol. 2005 Apr;26(4):1063-8.
350	Targeting nucleolin for better survival in diffuse large B-cell lymphoma.Leukemia. 2018 Mar;32(3):663-674. doi: 10.1038/leu.2017.215. Epub 2017 Jul 10.
351	Mechanisms of JP-8 jet fuel toxicity. I. Induction of apoptosis in rat lung epithelial cells.Toxicol Appl Pharmacol. 2001 Mar 1;171(2):94-106. doi: 10.1006/taap.2000.9108.
352	Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features.Cancer Med. 2016 Aug;5(8):1802-9. doi: 10.1002/cam4.753. Epub 2016 May 17.
353	Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population.Nat Genet. 2013 Jul;45(7):804-7. doi: 10.1038/ng.2666. Epub 2013 Jun 9.
354	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.Cancer. 2018 Feb 15;124(4):816-825. doi: 10.1002/cncr.31114. Epub 2017 Nov 10.
355	High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.Int J Hematol. 2015 Dec;102(6):662-9. doi: 10.1007/s12185-015-1880-3. Epub 2015 Oct 8.
356	Performance of a Commercially Available MAL Antibody in the Diagnosis of Primary Mediastinal Large B-Cell Lymphoma.Am J Surg Pathol. 2017 Feb;41(2):189-194. doi: 10.1097/PAS.0000000000000771.
357	Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas.Oncotarget. 2018 Jan 5;9(8):7928-7941. doi: 10.18632/oncotarget.23974. eCollection 2018 Jan 30.
358	Comprehensive cytogenetic analysis including multicolor spectral karyotyping and interphase fluorescence in situ hybridization in lymphoma diagnosis. a summary of 154 cases.Cancer Genet Cytogenet. 2003 May;143(1):73-9. doi: 10.1016/s0165-4608(02)00843-9.
359	MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.Lab Invest. 2019 Apr;99(4):539-550. doi: 10.1038/s41374-018-0152-2. Epub 2018 Nov 16.
360	MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.Br J Haematol. 2007 Aug;138(4):479-86. doi: 10.1111/j.1365-2141.2007.06680.x. Epub 2007 Jun 29.
361	Diffuse large B-cell lymphoma and its variants.Croat Med J. 2002 Oct;43(5):535-40.
362	ICT1 predicts a poor survival and correlated with cell proliferation in diffuse large B-cell lymphoma.Gene. 2017 Sep 5;627:255-262. doi: 10.1016/j.gene.2017.06.028. Epub 2017 Jun 16.
363	Expression and clinical significance of miR-23a and MTSS1 in diffuse large B-cell lymphoma.Oncol Lett. 2018 Jul;16(1):371-377. doi: 10.3892/ol.2018.8657. Epub 2018 May 7.
364	High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature.Leuk Lymphoma. 2013 Aug;54(8):1652-7. doi: 10.3109/10428194.2012.753445. Epub 2012 Dec 27.
365	Aberrant expression of napsin A in a subset of malignant lymphomas.Histol Histopathol. 2016 Feb;31(2):213-21. doi: 10.14670/HH-11-669. Epub 2015 Sep 24.
366	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.Blood. 2007 Sep 15;110(6):2067-74. doi: 10.1182/blood-2007-01-069575. Epub 2007 Jun 1.
367	Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use.Biol Direct. 2019 Nov 27;14(1):23. doi: 10.1186/s13062-019-0255-8.
368	B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.Blood. 2018 Oct 25;132(17):1805-1817. doi: 10.1182/blood-2018-03-841015. Epub 2018 Sep 12.
369	Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.J Clin Pathol. 2019 Apr;72(4):316-321. doi: 10.1136/jclinpath-2018-205584. Epub 2019 Feb 12.
370	NKL homeobox gene activities in B-cell development and lymphomas.PLoS One. 2018 Oct 11;13(10):e0205537. doi: 10.1371/journal.pone.0205537. eCollection 2018.
371	Immunoglobulin D (IgD) and IgD receptor expression in diffuse large B-cell lymphoma.Hematology. 2019 Dec;24(1):544-551. doi: 10.1080/16078454.2019.1642553.
372	Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.Blood. 2007 May 1;109(9):3922-8. doi: 10.1182/blood-2006-09-046391. Epub 2007 Jan 25.
373	Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.Mol Cancer Ther. 2017 Feb;16(2):285-299. doi: 10.1158/1535-7163.MCT-16-0390. Epub 2016 Dec 15.
374	Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.Oncotarget. 2016 Dec 6;7(49):80599-80611. doi: 10.18632/oncotarget.12413.
375	DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.Mol Cancer. 2014 May 27;13:125. doi: 10.1186/1476-4598-13-125.
376	PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.Oncotarget. 2016 Sep 13;7(37):59158-59172. doi: 10.18632/oncotarget.10993.
377	Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma.BMC Cancer. 2017 Dec 4;17(1):815. doi: 10.1186/s12885-017-3810-7.
378	A PER3 polymorphism is associated with better overall survival in diffuse large B-cell lymphoma in Mexican population.Cancer Biomark. 2015;15(5):699-705. doi: 10.3233/CBM-150511.
379	BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11294-9. doi: 10.1073/pnas.0903854106. Epub 2009 Jun 23.
380	PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients.Leuk Res. 2012 Nov;36(11):1365-9. doi: 10.1016/j.leukres.2012.07.008. Epub 2012 Aug 5.
381	Loss of expression of ZAC/PLAGL1 in diffuse large B-cell lymphoma is independent of promoter hypermethylation.Genes Chromosomes Cancer. 2010 May;49(5):480-6. doi: 10.1002/gcc.20758.
382	BTK(Cys481Ser) drives ibrutinib resistance via ERK1/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism.Blood. 2018 May 3;131(18):2047-2059. doi: 10.1182/blood-2017-10-811752. Epub 2018 Mar 1.
383	Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.Blood. 2007 Jan 1;109(1):271-80. doi: 10.1182/blood-2006-06-026500. Epub 2006 Sep 7.
384	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.PLoS One. 2019 Feb 25;14(2):e0212813. doi: 10.1371/journal.pone.0212813. eCollection 2019.
385	Clinical significance and functional validation of inorganic pyrophosphatase in diffuse large B cell lymphoma in humans.Cytotechnology. 2018 Apr;70(2):641-649. doi: 10.1007/s10616-017-0165-5. Epub 2017 Dec 12.
386	MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells.Exp Hematol. 2017 Feb;46:56-61.e1. doi: 10.1016/j.exphem.2016.09.011. Epub 2016 Oct 6.
387	Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.Anticancer Res. 2019 Sep;39(9):4925-4931. doi: 10.21873/anticanres.13680.
388	Association of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma.Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):736-44. doi: 10.1158/1055-9965.EPI-12-1014. Epub 2013 Feb 8.
389	The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.Leukemia. 2015 Mar;29(3):677-85. doi: 10.1038/leu.2014.264. Epub 2014 Sep 5.
390	ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex. Transl Res. 2016 Sep;175:129-143.e13. doi: 10.1016/j.trsl.2016.04.001. Epub 2016 Apr 13.
391	A Novel Non-Immunoglobulin (non-Ig)/BCL6 Translocation in Diffuse Large B-Cell Lymphoma Involving Chromosome 10q11.21 Loci and Review on Clinical Consequences of BCL6 Rearrangements.Pathol Oncol Res. 2016 Apr;22(2):233-43. doi: 10.1007/s12253-015-9972-1. Epub 2015 Aug 30.
392	The critical role of RasGRP4 in the growth of diffuse large B cell lymphoma.Cell Commun Signal. 2019 Aug 13;17(1):92. doi: 10.1186/s12964-019-0415-6.
393	Genetic alterations in the retinoblastoma protein-related p107 gene in human hematologic malignancies.Biochem Biophys Res Commun. 1998 Oct 9;251(1):264-8. doi: 10.1006/bbrc.1998.9459.
394	An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.Blood. 2015 Feb 5;125(6):959-66. doi: 10.1182/blood-2013-06-507152. Epub 2014 Nov 13.
395	Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.J Cancer Res Clin Oncol. 2019 Jun;145(6):1437-1448. doi: 10.1007/s00432-019-02909-z. Epub 2019 Apr 2.
396	Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome.Histopathology. 2010 Dec;57(6):785-95. doi: 10.1111/j.1365-2559.2010.03709.x.
397	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).Histopathology. 2017 Mar;70(4):595-621. doi: 10.1111/his.13106. Epub 2017 Jan 9.
398	Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy.Oncotarget. 2017 Feb 28;8(9):14912-14924. doi: 10.18632/oncotarget.14741.
399	Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA.Future Oncol. 2018 Oct;14(25):2627-2642. doi: 10.2217/fon-2018-0267. Epub 2018 Jun 18.
400	Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5' terminal oligopyrimidine tract.Oncogene. 2011 Mar 31;30(13):1531-41. doi: 10.1038/onc.2010.533. Epub 2010 Nov 22.
401	microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma.Nucleic Acids Res. 2011 Mar;39(5):1880-93. doi: 10.1093/nar/gkq1043. Epub 2010 Nov 9.
402	Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis.Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3111-6. doi: 10.1073/pnas.0910667107. Epub 2010 Feb 1.
403	Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models.Sci Rep. 2019 Nov 20;9(1):17161. doi: 10.1038/s41598-019-52985-x.
404	STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas.Nat Commun. 2018 Sep 12;9(1):3696. doi: 10.1038/s41467-018-06134-z.
405	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.Clin Cancer Res. 2019 Aug 15;25(16):5167-5176. doi: 10.1158/1078-0432.CCR-18-2718. Epub 2019 Jun 10.
406	Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study.BMC Cancer. 2014 May 14;14:333. doi: 10.1186/1471-2407-14-333.
407	Molecular signatures that can be transferred across different omics platforms.Bioinformatics. 2017 Jul 15;33(14):i333-i340. doi: 10.1093/bioinformatics/btx241.
408	Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.Oncotarget. 2015 Mar 20;6(8):5615-33. doi: 10.18632/oncotarget.3479.
409	A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region.Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1799-806. doi: 10.1158/1055-9965.EPI-12-0696. Epub 2012 Aug 21.
410	Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.Oncotarget. 2015 Mar 10;6(7):5059-71. doi: 10.18632/oncotarget.3239.
411	Loss of Ubr1 promotes aneuploidy and accelerates B-cell lymphomagenesis in TLX1/HOX11-transgenic mice.Oncogene. 2006 Sep 21;25(42):5752-63. doi: 10.1038/sj.onc.1209573. Epub 2006 Jul 24.
412	A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.Clin Cancer Res. 2011 Mar 15;17(6):1440-51. doi: 10.1158/1078-0432.CCR-10-1859. Epub 2011 Jan 25.
413	Genetic inactivation of TRAF3 in canine and human B-cell lymphoma.Blood. 2015 Feb 5;125(6):999-1005. doi: 10.1182/blood-2014-10-602714. Epub 2014 Dec 2.
414	TSPAN33 is a novel marker of activated and malignant B cells.Clin Immunol. 2013 Dec;149(3):388-99. doi: 10.1016/j.clim.2013.08.005. Epub 2013 Aug 15.
415	CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL.Cancer Res. 2017 Mar 1;77(5):1097-1107. doi: 10.1158/0008-5472.CAN-16-0786. Epub 2016 Dec 6.
416	Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.J Clin Pathol. 2019 Sep;72(9):630-635. doi: 10.1136/jclinpath-2019-205837. Epub 2019 Jun 12.
417	Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.Hum Pathol. 2007 Mar;38(3):500-7. doi: 10.1016/j.humpath.2006.09.020.
418	Preparation and Characterization of Fe(3)O(4)@MTX Magnetic Nanoparticles for Thermochemotherapy of Primary Central Nervous System Lymphoma in vitro and in vivo.Int J Nanomedicine. 2019 Dec 5;14:9647-9663. doi: 10.2147/IJN.S205456. eCollection 2019.
419	Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.Am J Surg Pathol. 2020 Feb;44(2):232-240. doi: 10.1097/PAS.0000000000001390.
420	Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies.Cancer Res. 2008 Jun 1;68(11):4116-22. doi: 10.1158/0008-5472.CAN-08-0085.